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ABSTRACT

The flavivirus resistance gene, Flv, in mice has been identified as 2′-5′
oligoadenylate synthetase 1b (Oas1b).

Susceptible mice produce a protein that is

truncated (Oas1btr) at the C-terminus due to a premature stop codon encoded by a C820T
transition. Mice produce 8 Oas1 proteins, Oas1a-Oas1h. In the present study, Oas1a,
Oas1b and Oas1btr were expressed as MBP-fusion proteins in bacteria and purified. 25A synthetase activity was demonstrated using MBP-Oas1a, while neither MBP-Oas1b
nor MBP-Oas1btr were functionally active. The 2-5A synthetase activity of MBP-Oas1a
was inhibited in a dose-dependent manner by the addition of MBP-Oas1b but not MBPOas1btr. Finally, three RNA probes were synthesized from the 3′ end of the WNV
Eg101 genome and used to test the ability of the expressed Oas1 proteins to bind to viral
RNA. Results of the RNA binding activity assays suggest Oas1 proteins may specifically
interact with regions of WNV RNA.
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FUNCTIONAL ANALYSIS OF THE MURINE OLIGOADENYLATE
SYNTHETASE 1b (Oas1b)

INTRODUCTION
General Characteristics of Flaviviruses
Previously part of the family Togaviridae, flaviviruses and pestiviruses were
reclassified as part of an evolutionarily distinct family, Flaviviridae.

The family

Flaviviridae consists of three genera: the flaviviruses, the pestiviruses and the
hepaciviruses.

In addition to these genera, GB viruses have been assigned to the

Flaviviridae family, but are not yet a genus. Flaviviridae belong to the positive-strand
RNA virus supergroup 2, which encode similar RNA-dependant RNA polymerases
(RdRp) (Lindenbach and Rice, 2001). Members of the family Flaviviridae share a
common gene order, replication strategy, and all lack a 3′ poly (A) tail.
The genus flavivirus currently contains ~70 viruses that are divided into 12
serogroups (Heinz et al., 2000), and includes a number of important human pathogens,
such as yellow fever virus (YFV), dengue virus (DV), Japanese encephalitis virus (JEV),
Murray Valley encephalitis virus (MVEV), St. Louis encephalitis virus (SLEV), West
Nile virus (WNV), and tick-borne encephalitis (TBE). The JEV serocomplex includes
JEV, MVEV, SLEV, WNV, Usutu virus, and Yaounde virus (Poidinger et al., 1996).
Many flaviviruses are transmitted between vertebrate hosts by mosquitos or ticks, and as
such, they are called “arboviruses” or arthropod-borne viruses. Approximately 50% of
flaviviruses are transmitted by mosquitos and 28% by ticks. No known arthropod vector
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has been identified for the remaining 22%, and they may be transmitted by rodent or bats
(Rice, 1996; Porterfield, 1996). WNV is a mosquito-borne virus that primarily infects
birds but can also infect humans (Bernard et al., 2001). West Nile virus was first isolated
in Uganda in 1937 (Smithburn et al., 1940). WNV has been endemic in the Middle East,
Africa, and western Asia; however, WNV recently expanded its geographical distribution
to the Western hemisphere (CDC, 2003; Petersen and Roehrig, 2001).
The flavivirus genome is a single-stranded RNA of positive polarity that is
involved in at least three cytoplasmic processes upon infection of the host cell: it acts as
an mRNA that is used to synthesize viral proteins, it serves as a template for RNA
replication, and it is targeted along with structural proteins for packaging into virions
(Lindenbach and Rice, 2001).

The flavivirus RNA genome contains a type I cap

(m7GppAMP) at the 5′ terminus and is the only animal RNA virus that lacks a 3′ poly (A)
tail. The genomic RNA of flaviviruses encodes a single open reading frame (ORF) that is
flanked by 5′ and 3′ untranslated regions (UTR) of about 100 and 600 nucleotides,
respectively (Rice, 2001). At the end of the 3′ UTR is a stem-loop structure that is
absolutely required for viral replication and is highly conserved among divergent
flaviviruses. A putative cyclization sequence in the 3′ UTR as well as its complementary
sequence in the capsid coding region of the 5′ end of the genome are present in the
genomes of all mosquito-borne flaviviruses (Brinton et al., 1986, You et al., 2001). A
single polyprotein precursor is translated from the large ORF. The viral polyprotein is
proteolytically processed by the viral serine protease (NS2B-NS3) and host cellular
proteases to produce ten mature viral proteins. Three viral structural proteins, capsid (C),
membrane (prM/M), and envelope (E) are encoded within the 5′ part of the viral RNA
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genome, while the 3′ portion of the genomic RNA encodes 7 nonstructural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Rice et al., 1985).

Molecular Biology of Flaviviruses
The flavivirus particle is small, spherical, and ~50 nm in diameter with an
electron-dense ribonucleoprotein core ranging from 20 to 30 nm in diameter. A hostderived lipid envelope surrounds the flavivirus particle (Murphy, 1980). Three viral
structural proteins are associated with the virion:

the E, prM/M, and C proteins

(Lindenbach and Rice, 2003). The mature C protein (~11 kDa) is thought to interact with
viral genomic RNA in the cytoplasm to form a nucleocapsid precursor (Lindenbach and
Rice, 2003); the charged residues at the N- and C- termini of the C protein presumably
mediate these interactions (Khromykh and Westaway, 1996).

The precursor of C,

anchored C, is cleaved at its C-terminus by the viral serine protease; the C-terminal
hydrophobic domain of C mediates translocation of prM to the ER prior to cleavage
(Amberg et al., 1994; Lobigs, 1993; Yamshchikov and Compans, 1994). The M protein
(~8 kDa) is a proteolytic fragment of its glycoprotein precursor, prM protein (~26 kDa).
Late in virus maturation, during egress of the virion, prM is cleaved into mature M
protein in the Golgi-network by furin, a convertase enzyme (Stadler et al., 1997). The
major virion surface protein is the E protein, a glycosylated type I integral membrane
protein that is ~53 kDa in size. In mature virions, E protein homodimers are arranged in
a head-to-tail conformation and lie parallel to the lipid bilayer (Heinz and Allison, 2000).
The E protein also forms heterodimers with prM, maintaining the E protein in a fusioninactive conformation until virion maturation via prM cleavage and release from the cell
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(Heinz and Allison, 2000). The E protein is a major antigenic determinant on the surface
of flavivirus particles; it mediates cell-receptor binding and fusion during entry of the
viral particle into the host cell, (Linderbach and Rice, 2003).
Although the complete mechanism for the formation of viral RNA replication
complexes has yet to be elucidated, interactions between viral nonstructural proteins and
between host cell proteins and the viral proteins may be required (Brinton, 2002). NS1 is
translocated to the ER and is subsequently released from the E protein by cleavage of a
signal sequence recognized by a signalase (Chambers et al., 1995). The eight C-terminal
residues of NS1 and ~140 N-terminal residues of NS2A are required for the cleavage of
NS1 from NS2A by an unknown host protease (Chambers et al., 1990; Hori and Lai,
1990; Falgout and Markoff, 1995; Pethel et al., 1992). Although mutations that prevent
cleavage at the NS1/NS2A junction have proven lethal, it is unclear what other functions
are carried out by NS2A (Lindenbach and Rice, 2003). NS2B is a membrane associated
protein that is required as a cofactor for the activity of the serine protease of NS3 which
cleaves at multiple sites in the viral polyprotein (Chambers et al, 1991, 1993). The NS3
sequence is highly conserved among flaviviruses. Based on data demonstrating RNAstimulated NTPase activity for the JEV NS3 (Kuo et al., 1999; Wengler and Wengler,
1991), and RNA helicase activity for the dengue 2 NS3 (Li et al., 1999), it seems likely
that NS3 is also involved in RNA replication. NS5 is the viral RNA-dependent RNA
polymerase and is the most conserved flavivirus protein.

NS5 also contains a

methyltransferase domain that may be involved in methylation of the 5′ cap structure of
the genomic RNA (Lindenbach and Rice, 2003; Koonin, 1993). Little is known about the
roles of NS4A and NS4B; although, recent studies have suggested that they may play a
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role in evading the host antiviral response by inhibition of interferon (IFN) signaling
(Munoz-Jordan et al., 2003; Lin et al., 2004; Liu et al., 2004; Liu et al., 2005). For
instance, Munoz-Jordan et al. (2005) suggested that the expression of NS4B of dengue-2
resulted in inhibition of signal transducers and activators of transcription-1 (STAT1)
nuclear translocation in response to IFN thereby blocking the IFN signaling cascade, and
that posttranslational cleavage of NS4A/NS4B by the viral protease NS3 is a prerequisite
for their IFN-antagonistic properties. JEV infection blocks tyrosine phosphorylation of
the cellular kinase, Tyk2, which is essential for IFN signaling (Lin et al., 2004). Several
nonstructural proteins of WNV, including NS4B have been shown to inhibit STAT1/2
phosphorylation (Liu et al., 2005). West Nile virus replication prevented activation of
Tyk2 and janus protein tyrosine kinase-1 (JAK) and therefore inhibited the signaling
mediated by IFN-α (Guo et al., 2005).
While only short regions within the 5′ UTR sequence are conserved among
different flaviviruses, the 5′-terminal structure it forms shares structural homology
between different flaviviruses (Brinton and Dispoto, 1988). The 3′ UTR of the minusstrand, which is the site of initiation of plus-strand synthesis, is complementary to the 5′
UTR. Deletions in the 5′ UTR of the plus-strand proved lethal for dengue 4 replication
(Cahour et al., 1995). Shi et al. (1996) detected 4 cell proteins in WNV-infected hamster
cells that bind to a probe comprised of the 3′ UTR of the minus-strand of WNV; TIAR
and TIA-1 were subsequently identified as 2 proteins that bound to this region of WNV
(Li et al, 2002). Similarly to the 5′ UTR, the flavivirus 3′ UTR contains only a few
conserved sequences (Lindenbach and Rice, 2003). However, a 3′ stem-loop (3′ SL)
consisting of 90 to 120 nucleotides forms a structure that is highly conserved among
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divergent flaviviruses (Brinton, 1986). Specific interactions of 3 hamster cell proteins,
one of which was subsequently identified as translation elongation factor 1A (EF1A),
with the 3′ SL of WNV RNA were reported (Blackwell and Brinton, 1995; Blackwell and
Brinton, 1997).
Flaviviruses enter the host cell by receptor-mediated endocytosis after binding of
the viral E protein to an unknown cell-surface receptor(s). Following cell entry, low-pH
induces fusion of virion envelops to host cell vesicle membranes in prelysosomal
endocytic compartments releasing the viral nucleocapsid into the cytoplasm where the
genomic RNA is uncoated by an unknown process (Lindenbach and Rice, 2003).
Flavivirus infection causes significant rearrangement and proliferation of cytoplasmic,
perinuclear endoplasmic reticular (ER) membranes (Brinton, 2002; Lindenbach and Rice,
2003; Knipe and Howley, 2001).

The genomic RNA is translated into a single

polyprotein that is cleaved at various sites by host and viral proteases to produce
structural and nonstructural viral proteins (Heinz et al., 1994).
Replication of the viral RNA is thought to occur in smooth membrane vesicle
clusters. However, these vesicle packets have only been observed late during infection
(Mackenzie et al., 1999); thus, the site of the early events of replication is still unknown.
Viral RNA replication begins by synthesis of a genome-length minus-strand RNA. The
duplex formed by viral minus- and plus-strand RNAs has been termed the replicative
form (RF); this RF is thought to serve as a template for synthesis of genomic RNA. The
replicative intermediate (RI) contains both single and double stranded regions,
presumably consisting of the minus-strand RNA template and nascent plus-strand RNAs
of different lengths generated by reinitiation; this allows more than one plus-strand RNA

7
to be synthesized from a single minus-strand RNA at a time (Baltimore et al., 1968;
Wengler et al., 1978; Cleaves and Dubin, 1979; Cleaves et al., 1981; Chu and Westaway,
1985). Although negative-strands continuously accumulate during infection, they have
been isolated in double-stranded forms only (Cleaves et al., 1981; Wengler et al., 1978).
The observed 10- to 100-fold excess of viral plus-strand RNAs over negative-strand
RNAs in infected cells has been attributed to a semiconservative and asymmetric mode of
replication (Cleaves et al., 1981; Chu and Westaway, 1985). Little is known about viral
packaging and release, although viral assembly occurs in association with rough ER
membranes (Lindenbach and Rice, 2003).

Accumulation of intracellular immature

virions in vesicles is followed by transport through the host secretory pathway where the
N-terminal portion of prM is cleaved in the Golgi-apparatus (Wengler, 1989; Stadler et
al., 1997). As the new virions are transported to the plasma membrane in vesicles, they
are released by exocytosis (Mason, 1989).

Genetic resistance to flavivirus-induced disease
Interactions between host-specific factors and viral components influence the
course and outcome of flaviviral infections (Bang, 1978). Observations of flavivirus
infections in horses, birds, rodents, humans, and non-human primates, suggest an innate
resistance to flavivirus-induced disease in some individuals from a number of species
(Shellam et al., 1998). Horses infected with WNV showed differential susceptibility to
WNV-induced disease (Bunning et al., 2002; Durand et al. 2000). Challenge of 4 species
of grouse with louping ill (LI) virus (a flavivirus) showed that three of the species (red
grouse, willow grouse, and ptarmigan) developed high levels of viremia and died. The
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fourth species (capercaillie) had very low levels of viremia and survived (Reid et al.,
1980). Similarly, yellow fever virus infection has been shown to be clinically mild in
African species of monkeys, while usually deadly in South American species of monkeys
(Shellam et al., 1998; Bauer and Mahaffy, 1930; Smithburn and Haddow, 1949).
Observations during two dengue virus epidemics in Cuba in 1981 and 1997 showed that
fewer blacks were hospitalized with dengue hemorrhagic fever/dengue shock syndrome
than whites suggesting the presence of a dengue resistance gene and that more blacks
than whites carried the resistant allele(s) (Kouri et al., 1987; Kouri et al., 1989; Guzman
et al., 1990). In 2002 in the Chicago area, 52 % of the population consisted of white
individuals but whites accounted for ~83 % of the individuals showing symptoms of
WNV-induced disease (Ruiz et al., 2004).

Although no resistance gene against

flavivirus-induced has yet been found in humans yet, a single gene in mice (Flv) has been
shown to affect the levels of virus production and the severity and outcome of disease
caused by flaviviruses (reviewed in Brinton, 1986).

Murine resistance to flavivirus-induced disease
Leslie Webster, in the 1920’s, established strains of mice that were either resistant
or susceptible to paratyphoid (bacterial) infection through selective breeding (Webster,
1923). Mouse strains resistant and susceptible to louping ill virus were also established
(Webster, 1933).

Independent segregation of bacterial and viral resistance was

demonstrated by establishment of mouse strains that showed resistance to only one type
of infection, either paratyphoid or louping ill virus infection but not both. Resistant mice
that survived louping ill virus challenge were later shown to be resistance to SLEV, a
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mosquito-borne virus, and Russian spring-summer virus, a tick-borne virus (Webster,
1937; Casals and Schnider, 1943). Subsequently, infection of the mice with a number of
different viruses showed that although resistance was conferred against both mosquitoand tick-borne flaviviruses, resistance did not extend to other types of viruses (Brinton
and Perelygin, 2003; and references therein). Monogenic, autosomal inheritance was
shown for the flavivirus resistance phenotype (Sabin, 1952). Production of a congenic
flavivirus-resistant C3H/RV strain was accomplished by the introduction of the resistance
gene carried by PRI mice into the flavivirus-susceptible C3H/He strain (Groschel and
Koprowski, 1965).

The C3H/RV strain was subsequently renamed C3H.PRI.Flvr

(Urosevic et al., 1999).
Although resistant mice are resistant to disease induced by all flaviviruses tested,
they are susceptible to flavivirus infection.

A number of factors such as route of

inoculation, dose and virulence of the infecting virus can all influence the outcome of
flavivirus infection in mice. For instance, C3H.PRI.Flvr mice show complete resistance
to intracerebral inoculation of YFV-17D vaccine, whereas intracerebral inoculation by
the more virulent WNV can kill the resistant mice.

Nevertheless, intracerebral

inoculation with 50,000 PFU of WNV resulted in 33 % mortality in resistant mice,
compared to 82 % mortality in susceptible ones after a 5,000 PFU intracerebral
inoculation of WNV (Brinton Darnell et al., 1974). Intraperitoneal injection of 108.5 PFU
WNV did not cause disease in resistant mice, while 50 % mortality was achieved in
susceptible mice after injection of 107.5 PFU of WNV intraperitoneally (Brinton, 1986).
Resistant mice produced much lower titers of flavivirus, and showed a slower spread of
infection as compared to congenic susceptible C3H/He mice (Shellam et al., 1998;
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Goodman and Koprowski, 1962; Brinton Darnell et al., 1974; Brinton Darnell and
Koprowski, 1974; Webster and Johnson, 1941; Vainio, 1963). Henson et al. (1969)
demonstrated that peak brain titers are 10,000 fold lower in resistant mice compared to
susceptible mice after a 105.5 PFU intracerebral inoculation of WNV; and that peak titers
were observed by day 3, with death on day 4, in susceptible mice and day 4, with death
on day 7 or 8 in resistant mice.
Intraperitoneal challenge with Banzi virus was lethal in C3H.PRI.Flvr mice that
were younger than 4 weeks old and full resistance was not achieved until the mice
reached 8 to 12 weeks (Bhatt and Jacoby, 1976). Suppression of the immune system
which prevented production of antiviral antibodies or T cells during Banzi virus infection
proved deleterious for both resistant and susceptible mice; suggesting an important role
for a mature and intact immune system in clearing flavivirus infection (Bhatt and Jacoby,
1976). Intracerebral inoculation of resistant mice with YFV-17D after injection with antiIFN antibodies showed no difference in their Flvr phenotype, illustrating that flavivirus
resistance is not mediated by interferon (Brinton et al., 1982).
WNV infection of primary cell cultures prepared from embryofibroblasts derived
from resistant and susceptible mice produced virus titers that differed by 10 to 100-fold
(Brinton Darnell and Koprowski, 1974). Interestingly, analysis of viral RNA produced in
embryofibroblast cultures from resistant and susceptible mice at very early times after
WNV infection showed that there were significantly lower amounts of plus-strand RNA
in the resistant cells than in the susceptible cells; both types of cells had the same amount
of negative-strand RNA (Brinton, 1981).
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Virus stress-induced genes
Viral stress-inducible genes (VSIG) consist of a common set of genes that are
inducible by viral infection, dsRNA and interferons (IFN). Stresses caused by viral
infection result in a strong and transient induction of these genes (Sarkar and Sen, 2004).
Although VSIG were initially discovered as IFN-inducible genes, they are capable of
being induced in an IFN-independent manner (Daly and Reich, 1993; Bandyopadhyay et
al., 1995; Weaver et al., 1998). Interestingly, microarray data suggest that the same
VSIG may be induced via different signaling pathways depending on the inducer (Der et
al., 1998; Zhu et al., 1998; Chang and Laimins, 2000; Geiss et al., 2001; Johnston et al.,
2001; Mossman et al., 2001; Geiss et al., 2002; Geiss et al., 2003). The IFN-stimulated
response element (ISRE) is a cis-acting sequence present in the promoters of all of these
genes.
Interferons are divided into type I and type II, and both types have antiviral
activity (Biron and Sen, 2001; Samuel, 2001; Finter, 1996). Both types of interferon are
structurally unrelated and their actions are mediated by different and structurally
unrelated cell-surface receptors (Sarkar and Sen, 2004). The type I IFN family includes
IFN-α, IFN-β, IFN-ω and IFN-τ; while IFN-γ is the only known type II interferon (Sarkar
and Sen, 2004). A positive regulatory domain (PRD) and a PRD-like element (PRD-LE)
are cis-acting elements present in the promoters of IFN-α and IFN-β, respectively; these
elements are inducible by interferon regulatory factors (IRFs) (Nakaya et al., 2001; and
references therein). The IRF-family transcription factors bind to the PRD/PRD-LEs and
ISREs present in the promoters of IFN and ISGs to induce the transcription of more than
a 100 genes involved in the antiviral signaling pathways, either IFN-dependent or
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independent (Nakaya et al., 2001). The prerequisite for Toll-like receptor 3 (TLR3), but
not other TLRs, for activation of dsRNA mediated gene induction was demonstrated in
dsRNA-unresponsive 293 cells that respond to dsRNA in the presence of exogenous
TLR3 and not other TLRs (Alexpoulou et al., 2001). The presence of viral dsRNA in
infected cells elicits phosphorylation of the cytoplasmic domain of TLR3 which leads to
activation of IRF3, which is constitutively expressed, via adaptor proteins (Jiang et al.,
2004). Once phosphorylated, IRF3 dimerizes and is then translocated to the nucleus
where it may form a complex with CBP and p300 forming double-stranded RNAactivated factor 1 (DRAF1) (Daly and Reich, 1995; Weaver et al., 1998). DRAF1 can
bind to ISREs in promoter regions of ISGs to activate transcription of genes such as
ISG15 and ISG54; DRAF1 also binds to PRD in the IFN-β promoter, inducing
transcription of IFN-β (Juang et al., 1998; Lin et al., 1998; Sato et al., 1998b; Wathelet et
al., 1998; Yoneyama, et al., 1998).

IFN produced in the infected cell is secreted and

binds to receptors on the surface of both infected cells and surrounding uninfected cells.
IFN binding to the IFN-α/b receptor (IFNAR) causes cross-activation of Jak1 and Tyk2,
which phosphorylate one another along with STAT1 and STAT2. The phosphorylated
STATs form IFN stimulated gene factor 3 (ISGF3), a trimeric complex including STAT1,
STAT2 and IRF9. The ISGF3 complex translocates to the nucleus where it binds to
ISREs in promoter regions to activate transcription of ISGs such as PKR, OAS family
members and IRF7 (Darnell et al., 1994; Stark et al., 1998; Nakaya et al., 2001). Once
phosphorylated due to viral dsRNA, IRF7 moves to the nucleus to further activate IFNα/β
promoters resulting in massive IFNα/β production that is maintained via a positive feedback loop (Nakaya et al., 2001; Marie et al., 1998; Sato et al., 1998a; Au et al., 1998).
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Gene induction by dsRNAs may be mediated by TLR3 and INF-independent
pathways.

The protein kinase RNA regulated (PKR) protein contains two dsRNA-

binding motifs (dsRBM) at its N-terminus; when inactive, the dsRBM2 of PKR binds the
C-terminal kinase domain (Clemens and Elia, 1997). PKR is in the inactive and closed
conformation until it interacts with dsRNA which causes the release of the kinase domain
from dsRBM2 allowing ATP binding resulting in autophosphorylation and activation
(Nanduri et al., 2000). Kumar et al. (1997) suggested the presence of a PKR-independent
mechanism of dsRNA signaling using PKR knock-out (PKR-/-) fibroblasts.

Such a

mechanism may involve members of the 2′-5′ oligoadenylate synthetase (OAS) family of
proteins which have been shown to be activated in the presence of dsRNA and ATP,
leading to degradation of viral and cellular RNAs by RNase L (Hovanessian, 1991;
Lengyel, 1987; Silverman and Cirino, 1997).

Chromosomal mapping and identification of the Flvr gene
Different alleles for natural resistance to Rickettsia tsutsugamushi, which causes
experimental scrub typhus in mice, were discovered in C3H/He and congenic
C3H.PRI.Flvr mice at the Ric locus on chromosome 5. C3H/He mice carry the Rics
(susceptible) allele, and C3H.PRI.Flvr mice carry the Ricr (resistant) allele (Groves et al.,
1980; Jerrells and Osterman, 1981).

A second locus tightly linked to Ric was

subsequently identified on chromosome 5 as rd (Lyon and Kirby, 1993). C3H/He mice
carry a recessive, defective allele of this gene, which causes retinal degeneration, while
the C3H.PRI.Flvr mice carry wild-type rd (Bowes et al., 1990; La Vail and Sideman,
1974). The differences in the Ric and rd loci in the two mouse strains seemed to
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segregate with the Flvr gene and the fact that these strains of mice are congenic,
suggested that the Flvr gene was linked to these two genes. Three-point backcross
linkage analyses using 4 chromosome 5 markers, Pgm-1, Eta-1 (Ric synonym), rd, and
Gus-s (glucuronidase structural gene), showed the gene order was Pgm-1, Eta-, rd, Flvr
and Gus-s (Sangster et al.,1994; Shellam et al., 1993). Based on mapping data obtained
by Urosevic et al. (1997), it was estimated that the Flv gene and the DMit159
microsatellite were less than 0.15 centiMorgans (cM) apart on mouse chromosome 5
(Perelygin et al., 2002). The distance was approximately equivalent to 309 kb and it was
highly likely (>95 %) that this distance downstream and upstream of the DMit159
microsatellite would contain the Flv locus (Perelygin et al., 2002).

Twenty-two genes,

including 10 loci that encoded 2′-5′ oligoadenylate synthetases, were identified
(Perelygin et al., 2002). The cDNAs from each of the 22 genes in this region from both
C3H.PRI.Flvr and C3H/He strains were amplified by RT-PCR, sequenced and compared.
Of the 22 gene sequences compared, only Oas1b and the Na+/Ca+-exchanger were
polymorphic; however the Na+/Ca+-exchanger was ruled out as there was no consistent
correlation between polymorphisms in this gene and the resistant phenotype (Perelygin et
al., 2002). The genomic and cDNA sequences of Oas1b revealed that the gene contained
6 exons and that 4 resistant mouse strains (BRVR, CASA/Rk, Cast/Ei, and C3H.PRI.
Flvr) encode an identical full-length protein; whereas in 5 susceptible mouse strains
(129/SvJ, BALB/c, C57BL/6, CBA/J and C3H.PRI. Flvr) an identical truncated protein
was encoded due to a C820T transition (Perelygin et al., 2002). The truncation of the
Oas1b protein was consistently correlated with the susceptible phenotype (Perelygin et
al., 2002).
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The Flv gene was identified as 2′-5′ oligoadenylate synthetase 1b, Oas1b
(Perelygin et al., 2002). The resistant allele was designated Flvr, and encodes a fulllength Oas1b protein. The susceptible allele was designated Flvs, and encodes a Cterminally truncated protein that also has two amino acid substitutions as compared to the
Flvr product. The minor resistance allele was designated Flvmr (Sangster et al., 1993),
and encodes a full-length Oas1b protein that has 14 amino acid substitutions as compared
to the Flvr product (Perelygin et al., 2002).

The 2′-5′ oligoadenylate synthetase family
Humans, horses, mice and other mammals produce 3 types of 2′-5′ oligoadenylate
synthetases: small encoded by the Oas1 gene(s), medium encoded by the Oas2 gene and
large encoded by the Oas3 gene.

Two Oas-like proteins that contain C-terminal

ubiquitin-like domains are also produced. The Oas1 unit consists of N- and C-terminal
domains that are unique to the 2′-5′ oligoadenylate synthetase family and contains a
central domain with a nucleotidyltransferase fold. The Oas2 and Oas3 genes consist of 2
and 3 Oas1 gene units, respectively. The Oas-like genes consist of the homologous Nterminus but contain a C-terminal ubiquitin-like domain (Hartmann et al, 1998). In
humans, genes in the family are designated OAS, unlike in mice where they are
designated Oas. The human OAS genes are located on chromosome 12, while in horses
they are located on chromosome 8 and in mice they are located on chromosome 5
(Perelygin et al., 2004). Recently, Hartmann et al (2003) reported the crystal structure of
the porcine OAS1 as a monomeric protein that is bilobal in structure. The first lobe of
the protein encompasses the large catalytic domain that is connected to the C-terminal
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domain by a helix-loop-helix linker. The N-terminus forms a short hook that packs
against the C-terminal domain to form a tether that maintains a fold which would allow
the domain-domain interactions that are required for enzymatic activity. The structure
formed has a negatively charged cleft containing the active site. Parallel to the cleft and
on the back face of the structure is a groove composed of positively charged residues in
which dsRNA is thought to bind. Binding of the dsRNA may cause a conformational
change that widens the cleft of the protein to allow recruitment of the substrate ATP
which then leads to the synthesis of 2′-5′ oligoadenylates (Hartmann et al., 2003). The
human OAS1 and the mouse Oas1a and Oas1g are functionally active 2′-5′
oligoadenylate synthetases. The human hOASL and its murine ortholog mOasl1 are not
functionally active, while the mouse mOasl2 was shown to be a functionally active
synthetase (Eskildsen et al., 2003).

Murine Oligoadenylate Synthetases
Mice produce 3 types of 2′-5′ oligoadenylate synthetases, small (40-47 kDa)
encoded by the Oas1a-Oas1h genes, medium (85-86 kDa) encoded by the Oas2 gene, and
large (126 kDa) encoded by the Oas3 gene. Mice also produce two Oas-like proteins.
The small 2′-5′ oligoadenylate synthetases contain 3 functional motifs; an N-terminal
LXXXP motif required for 2′-5′ oligoadenylate synthetase activity, a P-loop motif that
has been suggested to be required for ATP-binding, and a DAD Mg2+ binding motif also
required for synthetase function. Active 2′-5′ oligoadenylate synthetases bind doublestranded RNA and some double-stranded regions within folded single-stranded RNA
(Maitra et al., 1998; Desai et al., 1995; Sharp et al., 1999) and produce 2′-5′
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oligoadenylate by polymerizing ATP through 2′-5′ linkages.

One cellular defense

mechanism involves the activation of a latent endoribonuclease called RNase L. 2′-5′
oligoadenylates produced by activated 2-5A synthetases activate RNase L.

Once

activated, RNase L dimerizes and degrades viral and cellular single-stranded RNAs after
UA and UU dinucleotides (Wreschner, et al. 1981). Although the functions of 2′-5′
oligoadenylates and RNase L are virus non-specific (Hovanessian and Wood, 1980;
Clemens and Williams, 1978), the antiviral effect of the Oas1b gene product is specific to
members of the flavivirus genus (Perelygin et al., 2002).
Goals of the project
Resistance to flavivirus-induced disease was demonstrated in mice and showed
monogenic autosomal dominant inheritance. The flavivirus resistance gene, Flv, in mice
has been identified as 2′-5′ oligoadenylate synthetase 1b (Oas1b). Susceptible mice
produce a protein that is truncated (Oas1btr) at the C-terminus due to a premature stop
codon encoded by a C820T transition. The truncation comprises 30 % of the C-terminus
of the protein. Mice produce 8 Oas1 proteins, Oas1a-Oas1h. Oas1a and Oas1g were
previously reported to be functional 2-5A synthetases. Poly (I:C) binding was also
reported for Oas1a, Oas1c, Oas1d, Oas1e, Oas1f, Oas1g, Oas1h and Oas1btr proteins
(Kakuta et al., 2002). The full-length Oas1b had not yet been tested for either 2-5A
synthetase activity or RNA binding activity. The first goal of this project was to express
Oas1a, Oas1b and Oas1btr in bacteria and to purify the expressed proteins. The second
goal was to test the expressed Oas1 proteins for 2-5A synthetase activity to determine
whether Oas1b had synthetase activity. The final goal of the project was to test the
ability of the expressed Oas1 proteins to bind to synthetic and viral RNAs.
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MATERIALS AND METHODS
Cloning of Oas1 proteins into pMAL-c2G vectors: pHeTopoXL1a, previously
constructed by Dr. Perelygin, and primers containing the SnaBI and BamHI restriction
sites were used to clone the Oas1a gene into pCR-XL-TOPO with the TOPO-TA cloning
kit (Invitrogen). The construct was named pTopoXL1a#10. pTopoXL1a#10 and pMALc2G vector DNAs were digested with SnaBI and BamHI. The digestion was done
sequentially; briefly, pTopoXL1a#10 and pMAL-c2G DNAs were each digested with
BamHI and then QIAGEN’s PCR purification protocol was used to purify the DNA. The
cut pTopoXL1a#10 and pMAL-c2G DNAs were digested with SnaBI. The reactions
were then electrophoresed on a 1% TBE agarose gel. The vector and the 1101 bp Oas1a
gene insert were isolated using the QIAGEN Gel Extraction protocol.
pScreen1b#18, previously constructed by Dr. Scherbik, and primers containing
the SnaBI and BamHI restriction sites were used to clone the full-length Oas1b gene into
pCR-XL-TOPO by using the TOPO-TA cloning kit (Invitrogen). The construct was
named pTopoXL1b#1. pTopoXL1b#1 and pMAL-c2G vector DNAs were digested with
SnaBI and BamHI. The digestion was done sequentially; briefly, pTopoXL1b#1 and
pMAL-c2G DNAs were each digested with BamHI and then QIAGEN’s PCR
purification protocol was used to purify the DNA. The cut pTopoXL1b#1 and pMALc2G DNA were digested with SnaBI. The reactions were then electrophoresed on a 1%
TBE agarose gel. The vector and the 1128 bp Oas1b gene insert were isolated using the
QIAGEN Gel Extraction protocol.
Using the TOPO-TA cloning kit (Invitrogen), pTopoXL1btr#2, which contained
the Oas1btr gene, was constructed by using pTopoXL1b#1 as a template along with
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primers containing the SnaBI and BamHI. The BamHI-containing primer also encoded a
C-T transition in the Arg codon at position 757 resulting in a stop codon.
pTopoXL1btr#2 and pMAL-c2G vector DNAs were digested with SnaBI and BamHI.
The digestion was done sequentially; briefly, pTopoXL1btr#2 and pMAL-c2G DNAs
were each digested with BamHI and then QIAGEN’s PCR purification protocol was used
to purify the DNA. The cut pTopoXL1btr#2 and pMAL-c2G DNAs were digested with
SnaBI. The reactions were then electrophoresed on a 1% TBE agarose gel. The vector
and the 756 bp Oas1btr gene insert were isolated using the QIAGEN Gel Extraction
protocol.
The vectors and inserts were ligated using T4 DNA ligase according to a modified
protocol. Briefly, the vector and insert DNAs were heated to 45°C for 5 minutes and
cooled on ice prior to addition of the T4 DNA ligase.

The ligation reaction was

incubated at 16°C overnight. The reaction was then heated to 65°C to inactivate the
ligase and cooled on ice. The ligation reaction was then transformed into TOP10 One
Shot Chemically competent cells and plated on LB + AMP plates. The transformation
was modified to include two minutes of heat-shocking the competent cells and a longer
incubation than usual. PCR screening was performed on the colonies using primers
specific to the insert. The colonies were cultured and plasmid miniprep kits were used to
isolate plasmids from the cells. After isolating the plasmids, a sequencing reaction was
run on each plasmid using malE forward and M13/pUC reverse primers to check the
sequence.
Expression of MBP-Oas1 Proteins: pMAL-O1aQCR was used to transform
BL21 (non-D3E) cells for the expression of recombinant Oas1a (MBP-Oas1a) protein.
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Five mls of culture were grown overnight at 37°C. The 5 mls of overnight culture was
added to 250 mls of Rich Media with 0.05% glucose and 75 mg/ml of carbenicillin
(CRB) and grown at 37°C until the culture reached an OD600 of ~0.75. Two 1 ml
samples were collected and centrifuged at 14,000 x g for 2 minutes. The supernatant was
removed and the pellet was resuspended in 100 µl of 2x SDS buffer with 5 % βmercaptoethanol (β-ME); this was the uninduced sample. The rest of the culture was
induced with 1 mM IPTG overnight at 16°C. Two 1 ml samples were collected from the
overnight-induced culture and centrifuged at 14,000 x g for 2 minutes. The supernatant
was removed and the pellet was resuspended in 100 µl of 2x SDS buffer with βmercaptoethanol; this was the induced sample. The rest of the culture was pelleted by
centrifugation at 5,000 x g for 15 minutes.

The supernatant was removed and

resuspended in 5 ml of column buffer (20 mM tris-HCl, 200 mM NaCl, 1 mM EDTA and
10 mM β-ME) and frozen at -20°C until use.
pMAL-O1b was used to transform BL21 (nom-DE3) cells for expression of
recombinant Oas1b (MBP-Oas1b) protein. Five mls of culture were grown overnight at
37°C. The 5 mls of overnight culture was added to either 500 mls of TB Autoinduction
media (Novagen) with 0.05% glucose and 75 mg/ml of carbenicillin (CRB), or 500 mls
of LB media with 0.05% glucose and 75 mg/ml of carbenicillin (CRB); cultures were
grown at 37°C until the culture reached an OD600 of ~0.6. Two 1 ml samples were
collected and centrifuged at 14,000 x g for 2 minutes. The supernatant was removed and
the pellet was resuspended in 100 µl of 2x SDS buffer with 5 % β-ME; this was the
uninduced sample. The rest of the culture was either induced with 0.5 mM IPTG in LB
or allowed to grow for auto-induction without IPTG overnight at 16°C. Two 1 ml
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samples were collected from the overnight-induced culture and centrifuged at 14,000 x g
for 2 minutes. The supernatant was removed and the pellet was resuspended in 100 µl of
2x SDS buffer with 5 % β-ME; this was the induced sample. The rest of the culture was
pelleted by centrifugation at 5,000 x g for 15 minutes. The supernatant was removed and
resuspended in 3 ml of column buffer and frozen at -20°C until use.
pMAL-O1btr was used for the expression of recombinant Oas1btr (MBP-Oas1btr)
protein in BL21 (non-D3E) bacterial cells. Five mls of culture were grown overnight at
37°C. The 5 mls of overnight culture were added to 250 mls of Rich media with 0.05%
glucose and 75 mg/ml of carbenicillin (CRB) and grown at 37°C until the culture reached
an OD600 of ~0.5. Two 1 ml samples were collected and centrifuged at 14,000 x g for 2
minutes. The supernatant was removed and the pellet was resuspended in 100 µl of 2x
SDS buffer with 5 % β-ME; this was the uninduced sample. The rest of the culture was
induced with 0.5 mM IPTG overnight at 16°C. Two 1 ml samples were collected from
the overnight-induced culture and centrifuged at 14,000 x g for 2 minutes.

The

supernatant was removed and the pellet was resuspended in 100 µl of 2x SDS buffer with
5 % β-ME; this was the induced sample.

The rest of the culture was pelleted by

centrifugation at 5,000 x g for 15 minutes.

The supernatant was removed and

resuspended in 5 mls of column buffer and frozen at -20°C until further use.
Purification of MBP-Oas1 protein:

The Oas1 recombinant proteins were

successfully purified by column purification using amylose resin.

Cultures for the

expression of MBP-Oas1a, MBP-Oas1b and MBP-Oas1btr were prepared as described
above. The cultures were pelleted and the cells were resuspended in column buffer and
lysed using a French press.
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The soluble fraction (crude) and insoluble fraction were separated by
centrifugation at 10,000 x g for 20 minutes. The crude sample was diluted 1:5 in column
buffer and loaded onto a 2.5 cm x 10 cm column that contained 2 ml of equilibrated
amylose resin. The sample was allowed to flow through the column, collected and
reloaded onto the column three times to ensure that the protein efficiently bound to the
resin. The resin was washed with 100 ml of column buffer, and the MBP-fusion protein
was then eluted from the column with 10 mM maltose in column buffer.
Alternatively, the Oas1 proteins were purified using ion exchange
chromatography by loading the crude sample onto an anion exchange column (HiTrap Q
HP). The proteins in the samples were separated by a salt gradient. Buffer A is 20 mM
Tris-HCl, pH 7.6 and buffer B is 20 mM Tris-HCl, pH 7.6 and 1M NaCl. The MBPOas1a protein was eluted between concentrations of 550 mM and 800 mM NaCl. The
MBP-Oas1b protein was eluted between concentrations of 600 mM and 750 mM NaCl.
The MBP-Oas1btr protein was eluted between concentrations of 500 mM and 750 mM
NaCl. The protein concentrations obtained using the FPLC were very low and had to be
concentrated 100-fold to be visualized after SDS-PAGE.
Cleavage of the MBP fusion: In a reaction tube, 5.5 µl of Genenase I (1 µg/µl)
was added to 520 µl of MBP-Oas1a (600 ng/µl) and incubated at room temperature. Five
µl samples were taken from the digestion reaction at 2, 4, 24 and 28 hours. In a separate
tube, 5 µl of fusion protein were incubated for 28 hours; this was the mock digestion
sample. Five µl of fusion protein were mixed with 2X SDS gel-loading buffer with 5 %
β-ME at the end of the digestion period; this was the uncut fusion sample. Each sample
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was mixed with 2X SDS gel-loading buffer containing 5 % β-ME, boiled for 5 minutes
and stored at 4°C until analyzed. Samples were electrophoresed on a 10 % SDS-PAGE.
Separation of Oas1a from MBP by hydroxyapatite chromatography: One g
of hydroxyapatite was reconstituted in buffer C [20 mM sodium phosphate, 200 mM
NaCl (pH 7.2)]. The resin was allowed to settle and excess buffer was carefully decanted
as to not disturb the resin. Fresh buffer was added and this process was repeated twice.
The hydroxyapatite was poured into a disposable 1 x 10 cm column (BD Clontech). Five
hundred µl of the fusion protein cleavage mixture was loaded onto the column. The
column was washed with 80 ml of buffer C to wash away the maltose. Twenty ml of 0.5
M sodium phosphate (pH 7.2) were used to elute the Oas1a protein, the MBP fusion and
the protease. The column was reloaded twice more to ensure complete elution of protein.
The eluate was then loaded onto an amylose column. The flow-through was collected
and reloaded twice more to increase the efficiency of binding of the MBP fusion
fragment to the amylose resin. The flow-through was concentrated to 450 µl and stored
at -80°C until use.
Western blotting: MBP-Oas1 proteins were separated under denaturing and
reducing conditions on a 10 % SDS-PAGE. The proteins were transferred to a PVDF
membrane and the membrane was blocked overnight at 4°C with 5 % bovine serum
albumin (BSA) in Tris-buffered saline [10 mM Tris-HCl (pH 8.0), 150 mM NaCl] (TBS).
A horseradish peroxidase (HRP) conjugated anti-MBP (monoclonal murine antiMBP, New England Biolabs) antibody was used to detect the MBP-Oas1 proteins. The
membrane was incubated with antibody diluted 1:35,000 in a 5 % BSA-TBS solution at
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room temperature for 1.5 hrs. The membrane was washed with 15 ml of a 0.05 %
Tween-20-TBS solution (TBS-T) for 15 minutes 6-8 times.
For detection of the Oas1a protein after cleavage of MBP, an anti-OAS1 antibody
(chicken anti-human-OAS1 IgY, Genway Biotech) was used.

The membrane was

incubated with anti-OAS1 antibody diluted 1:2,000 in a 5 % BSA-TBS solution at room
temperature for 1.5 hrs. The membrane was washed with 15 ml of TBS-T for 15 minutes
6-8 times. The membrane was then incubated with a HRP-conjugated goat anti-IgY Fc
(Genway Biotech) antibody diluted 1:3,000 in a 5 % BSA-TBS-T solution at room
temperature for 1.5 hrs. The membrane was washed with 15 ml of TBS-T for 15 minutes
6-8 times.
After the last wash, West Pico Enhanced Chemiluminescence reagent (Pierce)
was added to the membrane for 5 minutes at room temperature. The membrane was
exposed with autoradiography film.
2′-5′ Oas activity assay: MBP-Oas1 fusion proteins were assayed for 2′-5′ Oas
activity. Each of the MBP-Oas1 fusion proteins was added to reaction mixtures at
increasing concentrations. The 50 µl reaction mixture contained 2′-5′ OAS activity assay
buffer (20 mM HEPES-KOH pH 7.5, 50 mM KCl, 25 mM Mg(OAC)2, 10 mM creatine
phosphate, 1U/µl creatine kinase, 5 mM ATP, and 7 mM β-ME), 50 µg/ml poly (I:C), 10
µCi 32p-ATP. The reaction was incubated at 30°C for 18 hrs. The synthesis reaction was
stopped by addition of 50 µl of 2x gel loading buffer (95% formamide, 18 mM EDTA,
0.025% SDS, xylene cyanol, and bromophenol blue). Four µl of each reaction were
loaded onto a 20% polyacrylamide gel and electrophoresed at 1800 V for 3.5 hrs. The
gel was exposed to an autoradiography film for 1-24 hrs.
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Synthesis of RNA probes: Three probes were constructed to test the ability of
the MBP-Oas1 fusion proteins to bind dsRNAs. The first probe, designated 3′ (+) UA
Probe #1, encompassed nucleotides 10387-10448 of the WNV Eg101 genome. The
second probe, designated 3′ (+) Control Probe #2, encompassed nucleotides 10308-10364
of the WNV Eg101 genome.

The third probe, designated 3′ (+) SL Probe #3,

encompassed bases 10931-11029 of the WNV Eg101 genome.

The probes were

synthesized using the in vitro T7 RNA polymerase MAXIscript protocol (Ambion) in the
presence of radiolabeled UTP (32p-UTP). The RNA transcripts were gel-purified and
partially purified by precipitation.
Gel electrophoresis mobility shift assay: The binding activity of each of the
MBP-Oas1 fusion proteins was tested by gel mobility shift assay using various RNA
probes from the 3′ end of the WNV genome. Proteins were added into binding reactions
containing 1X Gel Shift Buffer (3% Ficoll-400, 20 mM sodium phosphate pH 7.2, 60
mM KCl, 1 mM MgCl2, and 0.5 mM EDTA), 0.2 ul of RNasin, 35 ng of yeast tRNA as
non-specific competitor, 10 mM (DTT) dithiothreitol, and radiolabeled RNA. Reactions
were incubated at room temperature for 20 minutes and then stopped by the addition of
gel loading buffer (0.025% bromophenol blue, 0.025% xylene cyanol, 4% sucrose, and
1X Tris borate-EDTA).

The reactions were electrophoresed on non-denaturing 5%

polyacrylamide gels (39:1 acrylamide:bis-acrylamide, and 1X Tris borate-EDTA) at 120
V for 2 hrs. at 4°C. The gel was then dried and analyzed with a PhosphorImager.
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RESULTS
Cloning and expression of MBP-Oas1 proteins in bacteria
Initial attempts to express the full-length Oas1b protein using a pET16b
expression vector (Novagen) yielded proteins that were insoluble and were mainly in
inclusion bodies.

The concentrations of expressed proteins were inadequate for

purification. The expressed protein contained a 10X histidine tag at the N-terminus. The
use of different strains of bacteria and different growth and induction conditions failed to
alleviate the problems encountered with expression using the pET system (data not
shown). As a result, the pMAL Protein Fusion and Purification System was subsequently
used to express soluble Oas1b proteins that were fused to maltose binding protein (MBP).
Recombinant proteins expressed using the pMALc2G vector contained the MBP fusion at
the N-terminus and were soluble.
The cDNAs of the full-length and truncated Oas1b proteins as well as of the
Oas1a protein were each cloned into the pMAL-c2G expression vector. The expressed
fusion protein consisted of a 42.5 KDa maltose-binding protein linked to the Oas1 protein
by 10 Asp residues. Each of the constructs was used to express recombinant Oas protein
in BL21 bacterial cells. Cultures were grown at 37°C until an OD600 of approximately
0.6 was reached. The cultures were induced with IPTG overnight at 16°C. Samples were
collected and resuspended in 100 µl of 2X SDS gel loading buffer. Expression of the
fusion proteins was analyzed by electrophoresis of 15 µl from each sample on a 10 %
SDS polyacrylamide gel (Fig. 1).
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Figure 1: Expression of Oas1a, Oas1b and Oas1btr proteins in bacteria. Total proteins
were separated by 10% SDS-PAGE. (A) Expression of MBP-Oas1a in BL21 (non-DE3)
cells. Lane 1: Uninduced cells. Lane 2: Cells induced with 1mM IPTG overnight at
16°C. (B) Expression of MBP-Oas1btr in BL21 (non-DE3) cells. Lane 1: Uninduced
cells. Lane 2: Cells induced with 1mM IPTG overnight at 16°C. (C) Expression of
MBP-Oas1b in BL21 (non-DE3) cells. Lane 1: Uninduced cells. Lane 2: Cells
induced with 0.5mM IPTG overnight at 16°C. M: Molecular weight markers, Precision
Plus protein standards (Bio-Rad).
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Interestingly, the expression of MBP-Oas1a was more efficient than that of MBPOas1b and MBP-Oas1btr; also, the observed expression level of MBP-Oas1btr was
noticeably higher than that of MBP-Oas1b.

Purification of MBP-Oas1 fusion proteins
MBP-Oas1 fusion proteins were purified from cultures of BL21 bacterial cells.
Each of the expressed fusion proteins was soluble (Fig. 2A lane 3, Fig. 2B lane 3, Fig.
2C lane 1). Cell pellets from induced cultures were resuspended in column buffer
containing protease inhibitor cocktail to minimize protein degradation and all purification
steps were carried out at 4°C. The cells were lysed by using a French press and the
suspension was clarified by centrifugation. MBP-Oas1 fusion proteins were purified
using amylose resin as described in Methods.

Protein eluted from the resin was

concentrated by using Centricon YM-30 concentrators (Millipore) and separated by 10 %
SDS-PAGE.
MBP-Oas1a, MBP-Oas1b, and MBP-Oas1btr were successfully purified by
amylose resin column purification (Fig. 2A lanes 7 and 8, Fig. 2B lanes 6-8; Fig. 2C
lane 1). MBP-Oas1btr was initially purified by chromatography on an anion exchange
column (HiTrap Q HP) as described in Methods (Fig. 2D). Although extremely pure, the
amount of MBP-Oas1btr recovered using this method was not sufficient for
experimentation.

MBP-Oas1btr was subsequently purified using the amylose resin

column method to recover larger amounts of the protein. The presence of the MBP-Oas1
proteins was confirmed by Western blotting (Fig. 3); the proteins were detected using
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anti-MBP-HRP antibody. The results of these experiments confirmed the expression and
purification of MBP-Oas1 proteins using the pMAL system.
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Figure 2: Purification of Oas1 proteins. (A) Purification of MBP-Oas1a from BL21
(non-DE3) cells by amylose resin. Lane 1: Uninduced cells. Lane 2: Cells induced
with 1mM IPTG for 18 hrs at 16°C. Lane 3: Cell supernatant obtained after French press
lysis and centrifugation. Lane 4: Flow through #1. Lane 5: Wash #1. Lane 6: Flow
through #2. Lanes 7 & 8: Eluate. (B) Purification of MBP-Oas1b from BL21 (nonDE3) cells by amylose resin. Lane 1: Uninduced cells. Lane 2: Cells induced with
1mM IPTG for 18 hrs at 16°C. Lane 3: Cell supernatant after French press lysis and
centrifugation. Lane 4:

Flow through. Lane 5:

Wash. Lane 6-8: Eluate.

(C)
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Purification of MBP-Oas1btr with amylose resin.

Lane 1: Eluate.

Proteins were

fractionated by 10% SDS-PAGE. (D) Purification of MBP-Oas1btr by Ion Exchange
Chromatography. Lane 1: Eluate. M: Molecular weight marker, Precision Plus protein
standards (Bio-Rad).
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Figure 3: Representative western of MBP-Oas1 proteins purified by amylose resin.
Lane 1: MBP-Oas1b. Lane 2: MBP-Oas1a. Lane 3: MBP-Oas1btr. Proteins were
separated by 10 % SDS-PAGE. M: Molecular weight markers, Precision Plus protein
standards (Bio-Rad).
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Cleavage of MBP from the MBP-Oas1a fusion protein
Since the MBP-Oas1a fusion protein was the most abundant of the purified
proteins, it was used first to see if the MBP fusion could be removed by Genenase I
digestion and if Oas1a could successfully be recovered. Digestion with Genenase I was
fairly efficient, as there was only a small amount of the fusion protein which could be
visualized by gel staining compared to the uncut fusion after 28 hours of digestion (Fig 4,
lane 6).
kDa

100

MBP-Oas1a
-

75

50
Oas1a
MBP

37

M

1

2

3

4

5

6

Figure 4: Cleavage of Oas1a from MBP by Genenase I. Approximately 315 µg of
purified MBP-Oas1a were digested with Genenase I for 28 hours at room temperature.
Lane 1: 2 µl of a mock digestion containing protein only was incubated for 28 hrs Lane
2: 10 µl of uncut fusion protein Lane 3: 10 µl of protein digested for 2 hrs Lane 4: 10
µl of protein digested for 4 hrs Lane 5: 10 µl of protein digested for 24 hrs Lane 6: 10
µl of protein digested for 28 hrs M: Molecular weight markers, Precision Plus protein
standards (Bio-Rad). Proteins were separated by 10% SDS-PAGE.
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After digestion with Genenase I for 28 hrs, undigested MBP fusion protein was
separated from released Oas1a using hydroxyapatite and amylose resin chromatography
(Fig. 5A). Oas1a, the MBP fusion, and Genenase I were eluted from the column; coelution of Genenase I did not cause a problem since it was present, at most, as 1 % of the
eluted proteins. The eluted proteins were then loaded onto an amylose column to bind
both free MBP and uncut fusion proteins. However, a limitation of this technique is that
any MBP that has been denatured, damaged, or misfolded will not bind to the amylose
column and, so will not be removed from the flow-through. Indeed, MBP fusion, which
is 42.7 kDa, was detected comigrating with the purified Oas1a, which is 42.5 kDa; this
was demonstrated by comparing western blots done with anti-MBP-HRP antibody and
anti-OAS1 antibody. Although the SDS-PAGE showed a single band at ~43 kDa, this
same band was detected by both antibodies (Fig. 5B, lanes 3-4), indicating that some
MBP was still present in the purified Oas1a sample. Commercially available MBP2*
(42.5 kDa) was not detected with the anti-OAS1 antibody.
The results of these experiments show that although cleavage of MBP from Oas1a
was successful, it was not possible to separate the two cleavage products efficiently.
Although it may have been possible to separate these two proteins by different methods,
such as ion exchange chromatography, other methods were not employed due to the poor
recovery of the proteins. In order to investigate whether the removal of the MBP fusion
was necessary for synthetase activity, the 2′-5′ OAS activity of MBP-Oas1a was next
tested.
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Figure 5: Analysis of cleavage products by western blotting. (A) Proteins from a 28 hrs
Genenase I cleavage reaction were separated by 10% SDS-PAGE. Lane 1: MBP-Oas1a.
Lane 2: Control MBP2*. Lane 3: MBP-Oas1a digested for 24 hrs. Lane 4: Oas1a
separated by hydroxyapatite chromatography. (B) Representative western blots Lane 1:
Uncut MBP-Oas1a detected with anti-MBP-HRP antibody. Lane 2: Control MBP2*
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detected with anti-MBP-HRP antibody.

Lane 3:

Hydroxyapatite-purified cleavage

products detected with anti-OAS1 antibody. Lane 4: Hydroxyapatite-purified cleavage
products detected with anti-MBP-HRP antibodies.

M:

Molecular weight marker,

Precision Plus protein standards (Bio-Rad). Hydroxyapatite-purified cleavage products
were separated by 10% SDS-PAGE.

MBP-Oas1a is a functional synthetase
Based on the crystal structure of the porcine OAS1 protein, Hartmann et al.
(2003) predicted that the N-terminal hook of the porcine OAS1 would fold into the
protein and pack against the C-terminal domain to form a tether that would maintain a
fold which would allow the domain-domain interactions required for enzymatic activity.
This structure predicts that the presence of a fusion at the N-terminus of this protein
would prevent proper folding and abolish synthetase activity. However, human OAS1
shares greater homology with the porcine OAS1 than do the murine Oas1a or Oas1b
proteins.

Therefore, it was necessary to test whether an N-terminal fusion would

interfere with the enzymatic activity of murine Oas1a. Reaction mixtures containing 2′-5′
OAS buffer and different amounts of protein were incubated for 18 hrs at 30°C. The
products were separated by 20 % PAGE and the bands visualized by autoradiography.
Previously Kakuta et al. (2002) used bacterially expressed, unpurified Oas1a that
contained a 10X histidine tag at its N-terminus to demonstrate that recombinant Oas1a
was a functionally active synthetase.

MBP-Oas1a showed 2′-5′ OAS activity at

concentrations from 0.5 µg to 16 µg (Fig. 6, lanes 4-7). Purified Oas1a protein, which
had the MBP fusion removed, also showed 2′-5′ OAS activity (Fig. 6, lane 3).
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Comparison of the 2-5A synthesized by 0.75 µg of Oas1a and MBP-Oas1a showed that
the activities of the two proteins were similar. The lowest tested protein concentration
showing detectable synthetase activity was 0.75 µg for Oas1a and 0.5 µg MBP-Oas1a.
At concentrations lower than 0.5 µg no activity was detected (data not shown). MBP2*,
a commercially available maltose-binding protein, has the same amino acid sequence as
the MBP fusion except that it does not contain the 10 amino acid polylinker present in the
fusion protein. As a control, MBP2* was also tested for 2′-5′ OAS activity (Fig. 6, lane
2). MBP2* did not exhibit any 2′-5′ OAS activity indicating that the 2′-5′ OAS activity
shown by the fusion protein could not have been contributed by the MBP fusion. As
stated above, since free MBP was not completely removed from Oas1a after cleavage
with Genenase I, the Oas1a protein concentration measured was not accurate.
These results showed that bacterially expressed MBP-Oas1a and its cleaved
product, Oas1a, were enzymatically functional proteins. Such an observation suggests
that the proper folding of MBP-Oas1a into a catalytically active form was not hindered
by the presence of the MBP fusion. These results also indirectly confirmed that the
MBP-Oas1a protein was able to bind poly (I:C), since binding of poly (I:C) is required to
activate a 2′-5′ oligoadenylate synthetase.
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Figure 6: Analysis of the 2-5A synthetase activity of MBP-Oas1a. Different amounts of
MBP-Oas1a protein were incubated with α32p-ATP and poly (I:C) for 18 hrs at 30°C.
Four µl of each reaction were separated on a 20% polyacrylamide-urea denaturing gel.
Lane 1: No protein. Lane 2: 16 µg of MBP2*. Lane 3: 0.75 µg of Oas1a. Lane 4:
0.5 µg of MBP-Oas1a. Lane 5: 0.75 µg of MBP-Oas1a. Lane 6: 1 µg of MBP-Oas1a.
Lane 7: 16 µg of MBP-Oas1a.
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MBP-Oas1b is a non-functional oligoadenylate synthetase
A truncated form of Oas1b (Oas1btr) was previously cloned from the flavivirussusceptible C57BL/6J mouse strain, and expressed as an N-terminally 10X histidinetagged fusion protein in E. coli. When this Oas1btr was tested for 2-5A synthetase
activity, it was found to be enzymatically non-functional (Kakuta et al., 2002). In the
present study, both Oas1a and MBP-Oas1a were shown to have 2′-5′ OAS activity (Fig.
6, lane 3 and lanes 4-7, respectively); MBP-Oas1a was used as a positive control while
MBP-Oas1btr was used as a negative control. The full-length Oas1b, MBP-Oas1b, was
tested for synthetase activity. Reaction mixtures containing 2-5A synthetase buffer and
different amounts of protein were incubated for 18 hrs at 30°C. The products were
separated by 20 % PAGE and the bands visualized by autoradiography. Neither MBPOas1b nor MBP-Oas1btr showed any 2′-5′ OAS activity (Fig. 7, lane 3 and lane 2,
respectively) using 2.6 µg of each protein. This concentration was more than 4 times
higher than the lowest active concentration of MBP-Oas1a tested.

These results

demonstrate that MBP-Oas1b is not a functional 2-5A synthetase. However, preliminary
results suggest that MBP-Oas1b is able to bind ATP and modify it somehow.
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Figure 7: Analysis of the 2′-5′ OAS activity of MBP-Oas1b protein. Different amounts
of protein were incubated with α32p-ATP and poly (I:C). Two µl of each reaction were
separated on a 20% polyacrylamide-urea denaturing gel. Lane 1: No protein. Lane 2:
2.3 µg of MBP-Oas1btr. Lane 3: 2.6 µg of MBP-Oas1b. Lane 4: 1 µg of MBP-Oas1a.
Lane 5: 0.75 µg of MBP-Oas1a. Lane 6: 0.5 µg of MBP-Oas1a.
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WNV (+) 3′ RNA binding activity of MBP-Oas1 proteins
Activation of 2′-5′ Oas proteins requires the binding of dsRNA or some dsregions within ssRNA. Extensive base pairing is found in several small viral RNA
genomes (Maitra et al., 1998; Desai et al., 1995; Sharp et al., 1999).

To further

investigate the RNA binding activity of MBP-Oas1a, MBP-Oas1b, and MBP-Oas1btr, 3
radiolabeled RNA probes were constructed from different regions of the 3′ end of WNV
Eg101. The probes were folded using the mfold server (Zucher, 2003; Mathews et al.,
1999) (Fig. 8A) to check that they folded into the optimal secondary structure predicted
in a whole genome fold (Sgro and Palmenberg, unpublished data)(Fig. 8B).
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Figure 8: Secondary structure predictions of three WNV RNA probes using only the
stem-loop sequence (A) mfold Server (Zucher, 2003; Mathews et al., 1999) or (B) as part
of a whole genome fold (Sgro and Palmenberg, unpublished data).
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The first probe tested was (+) 3′ UA Probe #1, which encompassed nucleotides
10387-10448 of the WNV Eg101 genome. The sequence of this probe spans the last 10
nucleotides of the NS5 viral gene including the stop codon and the first 57 nucleotides of
the 3′ UTR. This probe has a sequence that is AU-rich. To determine the optimal
concentration of non-specific competitor that should be included in RNA binding
reactions, MBP2* in large excess (16 µg) was incubated with (+) 3′ UA Probe #1 in the
presence of increasing concentrations of yeast tRNA (Fig. 9). The data indicated that
~100 ng of tRNA would be sufficient to compete out most of the non-specific binding to
MBP2* when it is present in large excess (4 to 16 times) compared to the concentrations
used in subsequent gel mobility shift assays. The majority of the non-specific binding
activity was competed by the addition of as little as 10 ng of yeast tRNA.
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Figure 9: Gel mobility shift assay to determine the optimal non-specific competitor
concentration. MBP2* (16 µg) was incubated with (+) 3′ UA Probe #1 (2000 cpm) and
increasing concentrations of tRNA. The amounts of competitor were: Lane 1: 0. Lane
2: 5 ng. Lane 3: 10 ng. Lane 4: 25 ng. Lane 5: 50 ng. Lane 6: 75 ng. Lane 7: 100
ng. FP: Free probe. Binding reactions were separated on a 6 % polyacrylamide nondenaturing gel. Bands on the dried gel were detected by A. PhosphorImaging. B.
Autoradiography.
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Based on these results, 30-50 ng of yeast tRNA was used to compete out nonspecific binding to the MBP-portion of the fusion proteins and free MBP in the samples.
A MBP2* reaction that contained 2 times the highest amount of fusion protein used in the
assay was included in each subsequent gel shift experiment. Different concentrations of
MBP-Oas1a (200 to 800 ng) and MBP-Oas1b (200 to 600 ng) were next used to test their
ability to bind to (+) 3′ UA Probe #1 (Fig. 10).
MBP-Oas1a
FP

1
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Figure 10: Gel shift mobility assay with (+) 3′ UA Probe #1. Various concentrations of
MBP-Oas1a (lanes 2-5) or MBP-Oas1b (lanes 6-8) were incubated with (+) 3′ UA Probe
#1 (2000 cpm). Lane 1: Free probe. Lane 2: 200 ng of MBP-Oas1a. Lane 3: 400 ng
of MBP-Oas1a. Lane 4: 600 ng of MBP-Oas1a. Lane 5: 800 ng of MBP-Oas1a. Lane
6: 200 ng of MBP-Oas1b. Lane 7: 400 ng of MBP-Oas1b. Lane 8: 600 ng of MBPOas1b. Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.
Bands on the dried gel were detected by A. PhosphorImaging. B. Autoradiography.
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These results indicated that both MBP-Oas1a and MBP-Oas1b can bind to (+) 3′
UA Probe #1; however, the MBP-Oas1b appeared to have a higher binding activity to
this probe than MBP-Oas1a. To determine the lowest concentration at which these
proteins bind this RNA probe, MBP-Oas1b and MBP-Oas1a at different concentrations
below 200 ng were incubated with (+) 3′ UA Probe #1. MBP-Oas1b could bind to this
RNA probe at concentrations below 10 ng of protein (Fig. 11), while RNA binding
activity was not detected at 10 ng with MBP-Oas1a (Fig. 12).

MBP-Oas1btr at

concentrations of 10 to 100 ng did not exhibit any binding to (+) 3′ UA Probe #1 (Fig.
13). MBP2* did not exhibit any binding activity at concentrations twice that of the
highest tested concentrations of MBP-Oas1a and MBP-Oas1b, suggesting that the
binding of the two Oas1 fusion proteins to (+) 3′ Probe #1, was specific.
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Figure 11: Effect of MBP-Oas1b concentration on binding activity to (+) 3′ UA Probe
#1. Binding was tested using increasing concentrations of MBP-Oas1b and 2000 cpm of
(+) 3′ UA Probe #1. Lane 1: 200 ng of control MBP2*. Lane 2: 10 ng of MBP-Oas1b.
Lane 3: 25 ng of MBP-Oas1b. Lane 4: 50 ng of MBP-Oas1b. Lane 5: 75 ng of MBPOas1b. Lane 6: 100 ng of MBP-Oas1b. Lane 7: 200 ng of MBP-Oas1b. FP: Free
probe. Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.
Bands on the dried gel were detected by A. PhosphorImaging. B. Autoradiography.
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Figure 12: Effect of MBP-Oas1a concentration on binding activity to (+) 3′ UA Probe
#1. Binding was tested using increasing concentrations of MBP-Oas1a and 2000 cpm of
(+) 3′ UA Probe #1. Lane 1: 400 ng of control MBP2*. Lane 2: 10 ng of MBP-Oas1a.
Lane 3: 25 ng of MBP-Oas1a. Lane 4: 50 ng of MBP-Oas1a. Lane 5: 75 ng of MBPOas1a. Lane 6: 100 ng of MBP-Oas1a. Lane 7: 200 ng of MBP-Oas1a. Lane 8: 400
ng of MBP-Oas1a. FP:

Free probe.

polyacrylamide non-denaturing gel.

Binding reactions were separated on a 6 %
Bands on the dried gel were detected by A.

PhosphorImaging. B. Autoradiography.
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Figure 13: Effect of MBP-Oas1btr concentration on binding activity to (+) 3′ UA Probe
#1. Binding was tested using increasing concentrations of MBP-Oas1btr and 2000 cpm
of (+) 3′ UA Probe #1. Lane 1: 200 ng of control MBP2*. Lane 2: 10 ng of MBPOas1btr. Lane 3: 25 ng of MBP-Oas1btr. Lane 4: 50 ng of MBP-Oas1btr. Lane 5: 75
ng of MBP-Oas1btr. Lane 6: 100 ng of MBP-Oas1btr.

Lane 7: 200 ng of MBP-

Oas1btr. FP: Free probe. Binding reactions were separated on a 6 % polyacrylamide
non-denaturing gel. Bands on the dried gel were detected by A. PhosphorImaging. B.
Autoradiography.
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The next RNA probe tested was the (+) 3′ Control Probe #2, which encompasses
nucleotides 10308-10364 of the WNV Eg101 genome. The (+) 3′ Control Probe #2 is
located in the 3′ end of the NS5 gene of WNV Eg101 and is also rich in As and Us.
Although it has a secondary structure that is similar to (+) 3′ UA Probe #1, it does not
contain uninterrupted single-stranded stretches of As and Us that are as long as those in
(+) 3′ UA Probe #1. MBP-Oas1 protein concentrations of 25 ng, 50 ng, and 100 ng were
used to test the efficiency of binding of this protein to (+) 3′ Control Probe #2 (Fig. 14,
for MBP-Oas1b and MBP-Oas1a; Fig. 15, for MBP-Oas1b and MBP-Oas1btr).
MBP-Oas1b but neither MBP-Oas1a nor MBP-Oas1btr exhibited detectable binding to
the (+) 3′ Control Probe #2. Notably, the relative binding activity of MBP-Oas1b to this
RNA probe was similar to that observed with (+) 3′ UA Probe #1. However, competition
gel shift assays using these two probes are required to quantify these interactions.
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Gel mobility shift assay with (+) 3′ Control Probe #2.

Increasing

concentrations of MBP-Oas1b or MBP-Oas1a were incubated with (+) 3′ Control Probe
#2 (1000 cpm). Lane 1: Free probe. Lane 2: 25 ng of MBP-Oas1b. Lane 3: 50 ng of
MBP-Oas1b. Lane 4: 100 ng of MBP-Oas1b. Lane 5: 25 ng of MBP-Oas1a. Lane 6:
50 ng of MBP-Oas1a.

Lane 7: 100 ng of MBP-Oas1a. Lane 8: 100 ng of control

MBP2*. Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.
Bands on the dried gel were detected by A. PhosphorImaging. B. Autoradiography.
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Gel mobility shift assay with (+) 3′ Control Probe #2.

Increasing

concentrations of MBP-Oas1b or MBP-Oas1btr were incubated with (+) 3′ Control Probe
#2 (1000 cpm). Lane 1: Free probe. Lane 2: 25 ng of MBP-Oas1b. Lane 3: 50 ng of
MBP-Oas1b. Lane 4: 100 ng of MBP-Oas1b. Lane 5: 25 ng of MBP-Oas1btr. Lane 6:
50 ng of MBP-Oas1btr. Lane 7: 100 ng of MBP-Oas1btr. Lane 8: 100 ng of control
MBP2*. Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.
Bands on the dried gel were detected by A. PhosphorImaging. B. Autoradiography.
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The last probe tested was (+) 3′ SL Probe #3, which comprised the 3′ terminal
stem-loop structure of WNV Eg101. MBP-Oas1 protein at concentrations of 25 ng, 50
ng, and 100 ng were used to test the binding activity of this protein to (+) 3′ SL Probe #3
(Fig. 16, for MBP-Oas1b and MBP-Oas1btr; Fig. 17, for MBP-Oas1b and MBPOas1a). Interestingly, this probe did not bind to any of the Oas1 fusion proteins. This is
the longest of the probes used and it contains the longest stretches of dsRNA.
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Figure 16: Gel mobility shift assay with (+) 3′ SL Probe #3. Increasing concentrations
of MBP-Oas1b or MBP-Oas1btr were incubated with (+) 3′ SL Probe #3 (1000 cpm).
Lane 1: Free probe. Lane 2: 25 ng of MBP-Oas1b. Lane 3: 50 ng of MBP-Oas1b.
Lane 4: 100 ng of MBP-Oas1b. Lane 5: 25 ng of MBP-Oas1btr. Lane 6: 50 ng of
MBP-Oas1btr. Lane 7: 100 ng of MBP-Oas1btr. Lane 8: 100 ng of control MBP2*.
Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel. Bands on
the dried gel were detected by A. PhosphorImaging. B. Autoradiography.
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Figure 17: Gel mobility shift assay with (+) 3′ SL Probe #3. Increasing concentrations
of MBP-Oas1b or MBP-Oas1a were incubated with (+) 3′ SL Probe #3 (1000 cpm).
Lane 1: Free probe. Lane 2: 25 ng of MBP-Oas1b. Lane 3: 50 ng of MBP-Oas1b.
Lane 4: 100 ng of MBP-Oas1b. Lane 5: 25 ng of MBP-Oas1a. Lane 6: 50 ng of
MBP-Oas1a.

Lane 7: 100 ng of MBP-Oas1a. Lane 8: 100 ng of control MBP2*.

Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel. Bands on
the dried gel were detected by A. PhosphorImaging. B. Autoradiography.
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MBP-Oas1b but not MBP-Oas1btr inhibits MBP-Oas1a synthetase activity in vitro
Addition of Oas1d, a non-functional synthetase, to Oas1a in 2-5A synthetase
reactions was recently reported to have an inhibitory effect on the synthetase activity of
Oas1a (Yan et al., 2005). To investigate whether the non-functional MBP-Oas1b or
MBP-Oas1btr could inhibit the synthetase activity of MBP-Oas1a in vitro, 2-5A
synthetase reactions containing 1 µg of MBP-Oas1a and increasing amounts of either
MBP-Oas1b or MBP-Oas1btr (0, 0.5X, 1X, 1.5X, and 2X) were analyzed. The results
showed that MBP-Oas1b inhibited MBP-Oas1a synthetase activity in a dose-dependant
manner (Fig. 18, lanes 2-6). However, this inhibitory effect was not observed after the
addition of MBP-Oas1btr (Fig. 18, lanes 7-10). Both ATP and poly (I:C) were in excess
in these reactions.
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Figure 18: Inhibition of MBP-Oas1a synthetase activity. All reactions contained α32pATP, poly (I:C), and 1 µg of MBP-Oas1a, except Lane 1, which contained no proteins.
In addition to MBP-Oas1a, reactions also contained: Lanes 2-6: 0, 0.5X, 1X, 1.5X, or 2X
of MBP-Oas1b, respectively. Lanes 7-10: 0, 0.5X, 1X, 1.5X, or 2X of MBP-Oas1btr,
respectively. Four µl of each reaction were separated on a 20% polyacrylamide-urea
denaturing gel.
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DISCUSSION
Expression and Purification of murine Oas1 proteins
Kakuta et al. (2002), expressed Oas1btr using the pET expression system in a
previous study. The expressed Oas1btr protein was not purified; instead crude cell
extracts were used in their studies of Oas1 synthetase activity and poly (I:C) binding. In
the present study, efficient and soluble expression of murine Oas1b was not achieved
using the pET system.

To investigate whether poor expression levels were a

characteristic of the Oas1b protein, Oas1btr was next expressed using the pET expression
system. Expression levels of Oas1btr were not significantly greater than of Oas1b; the
solubility of Oas1btr was not determined. Expression of Oas1a was not attempted using
this system. It is not clear why the levels of soluble Oas1b/btr were so low when
expressed using this system. Oas1a shares 82% amino acid sequence homology with
Oas1b, with the greatest variability in the C-terminus and the next greatest variability in
the N-terminus.

The two proteins are most homologous within the central,

nucleotidyltransferase domain. Hydrophobicity plots of the amino acid sequences of both
Oas1a and Oas1b showed that the tail of the Oas1b protein is more hydrophobic than that
of Oas1a. The hydrophobic sequence at the C-terminus of Oas1b may have contributed
to the expression of insoluble protein using the pET expression system.
Subsequently, the pMAL Protein Fusion and Purification System was used to
express Oas1a, Oas1b and Oas1btr as MBP-fusion proteins in bacteria. All 3 of the Oas1
proteins expressed using the pMAL system were soluble and expressed at levels adequate
for purification.

However, the observed expression level of MBP-Oas1a was

significantly higher than that of either MBP-Oas1btr or MBP-Oas1b. Relative to MBP-
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Oas1b, MBP-Oas1btr was expressed at lower levels.

The purified proteins were

subsequently used in in vitro 2-5A synthetase assays and in gel shift mobility assays with
RNA probes from the 3′ end of the WNV genomic RNA.

2′-5′ oligoadenylate synthetase activity
Oas1a and Oas1g were previously reported to be functional 2′-5′ oligoadenylate
synthetases (Kakuta et al., 2002). In that study, Oas1 proteins in bacterial lysates were
incubated with poly (I:C)-agarose bead, the bound proteins were then used in a 2-5A
synthetase activity assay.

Using this technique, variation in activation of the Oas1

proteins by poly (I:C) could in part be due to differences in the poly (I:C) binding
activities of the tested proteins. Bacterial proteins present in the crude cell extracts also
may compete with Oas1 proteins for binding of poly (I:C), producing results that may be
unreliable. Although Oas1btr was tested by Kakuta et al. (2002) and found not to be
active, it was found to bind poly (I:C). Full-length Oas1b was not previously tested for
RNA binding or synthetase activity. In the present study, neither MBP-Oas1b nor MBPOas1btr showed detectable 2-5A synthetase activity. Under the same conditions, MBPOas1a produced 2-5A oligomers.
A previous study showed that enzyme activity was almost completely lost when
mutations were introduced in the putative active sites of human OAS isozymes (Sarkar et
al., 2002). The Oas1b protein contains R90Q and R91Q substitutions in the substrate
binding acceptor site, and also S203R and K209T substitutions in the substrate binding
donor site. Oas1b also has a 4 amino acid deletion in the P-loop which may prevent it
from folding into a catalytically functional structure. These mutations predicted that the
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full-length Oas1b protein would not be an active synthetase. The results in the present
study confirmed the prediction that Oas1b is not a functional 2-5A synthetase.
The production of 2-5A and its subsequent activation of RNase L are important
components of one of the IFN-induced antiviral pathways in cells. There is a growing
amount of evidence that 2-5A synthetases can participate in non-enzymatic cellular
functions.

For instance, an alternatively spliced product of the human OAS1 gene

designated 9-2/E17 is an active synthetase. Interestingly, this isozyme also contains a
BH3 domain through which it has been reported to interact with Bcl-2 family proteins
inducing apoptosis (Ghosh et al., 2001), demonstrating that this protein has two mutually
independent activities, namely, synthesizing 2-5A and promoting apoptosis. A yeast twohybrid system was used to screen a human B cell cDNA library with PRL-R (prolactin
receptor) and a human OAS1 isoform was reported to interact with PRL-R.
Overexpression of the human OAS1 decreased the basal activity of both the IRF-1 and βcasein promoters by 40-60 % via an RNase L-independent mechanism (McAveney et al.,
2000; Zhou et al., 1993). Overexpression of both PRL and OAS1 decreased IRF-1
promoter activity by 60% (McAveney et al., 2000).

Inhibition of Oas1a synthetase activity
Human OAS1 proteins have a CFK motif at their C-terminus which is required
for tetramerization of these proteins (Ghosh et al., 1997). Hartmann et al. (2003) reported
that the porcine OAS1, which is 73 % identical in sequence to human OAS1, crystallized
as a monomeric protein. Amino acids important for folding of the porcine OAS1 and the
mouse Oas1b share an overall identity of 56 % (Hartmann et al., 2003). The ability of
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mouse Oas1 proteins to multimerize has not yet been investigated. The CFK motif is
conserved in the full-length Oas1b protein, but the Oas1a protein contains a K to I
substitution in this motif and it is possible that this mutation could affect protein-protein
interactions facilitated via the CFK motif. Yan et al. (2005) demonstrated that Oas1a
synthetase activity was inhibited by addition of Oas1d in vitro, presumably via direct
protein-protein interactions. Once activated by dsRNA, Oas1a is ubiquitously expressed
in multiple tissues. The ovary-specific expression pattern of Oas1d, suggests a role for
this protein during oogenesis and/or embryogenesis. Oas1c and Oas1e, which are other
non-functional synthetases, are also abundantly expressed in oocytes.

Upon viral

infection, the Oas1a-mediated IFN response is ubiquitous. The authors suggest that this
inhibitory effect of Oas1d could serve a protective function by blocking or downregulating the IFN/OAS/RNase L RNA degradation pathway to prevent the loss of
oocytes during acute viral infection; thus maintaining female fertility. However, Oas1d
may have an RNase L independent function in regulating development.
In the present study, MBP-Oas1b was shown to inhibit MBP-Oas1a synthetase
activity. The resistant phenotype is characterized by a 100-fold or more decrease in the
amount of intracellular viral RNA; thus, any inhibition of Oas1a synthetase activity by
Oas1b in vivo would be inconsistent with the theory that a mechanism involving RNase L
mediated viral RNA degradation via 2-5A synthetase activity confers flavivirus
resistance. In support of the validity of the interaction between MBP-Oas1a and MBPOas1b, the inhibitory effect was not observed after the addition of MBP-Oas1btr (Fig 18,
lanes 7-10).

Oas1btr has a C-terminal truncation that may prevent protein-protein

interactions. The results of the present study showed that MBP-Oas1b is not a functional
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synthetase and that it can inhibit the 2-5A synthetase activity of Oas1a. These data
suggest that Oas1b confers the flavivirus resistance phenotype through a mechanism that
is independent of the RNase L-RNA degradation pathway.

RNA binding activity
Poly (I:C) has been used as the standard activator of IFN and OAS for decades
(Minks et al., 1979); however, it is a synthetic RNA that is not present in cells. Poly (I:C)
consists of double strands formed by homopolymers that are not interrupted by singlestranded bulges or loops. Cellular RNAs are single-stranded but can form secondary and
tertiary interactions. Longer synthetic dsRNAs (40 to 110 bp) have been reported to
activate 2-5A synthetases more efficiently than shorter dsRNAs (25 bp) at subsaturating
concentrations of ~100 nM (Desai and Sen, 1997). Full activation by the short dsRNAs
is only observed at saturating concentrations (Sarkar et al., 1999). Han and Barton
(2002) reported a threshold concentration of 20 nM of HCV mRNA for activation of
human 2-5A synthetase. In comparison to the standard poly (I:C) concentration used for
activation of 2-5A synthetases (50 µg/ml), full activation of human 2-5A synthetase
activity in HeLa cell extracts by HCV genome RNA (~9.6 kb) required a concentration
of ~350 µg/ml. These observations suggest that although a high level of activation of 25A synthetases is achieved by relatively low concentrations of poly (I:C), the
physiological levels of viral RNAs in infected cells would not be sufficient to achieve
significant levels of RNase L activation until late in the infection cycle. The effect of the
flavivirus resistance phenotype on viral RNA can be observed as early as 2 hrs after
infection (Yan and Brinton, unpublished data).
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Kakuta et al. (2002) reported RNA binding activity of Oas1a and Oas1btr using
poly (I:C)-agarose beads that were incubated with crude cell lysates prepared from
bacterial cultures expressing Oas1 proteins. The bound Oas1 proteins were detected
using anti-His antibody. All Oas1 proteins tested in that study exhibited binding to poly
(I:C). However, some of the binding activity observed could have been due to other
bacterial proteins, similar in size to the Oas1 proteins and with His-rich regions, which
may non-specifically bind. The anti-His antibody can detect cell proteins rich in His
residues, such as heat-shock proteins. Because poly (I:C)-agarose beads are no longer
commercially available and because attempts to make poly (I:C)-agarose beads in the lab
failed, poly (I:C)-agarose beads were not used to study Oas1 protein-RNA interactions.
However, poly (I:C) was used to activate Oas1 synthetase activity.

RNA probes

synthesized from the 3′ end of WNV Eg101 were used to compare the RNA binding
activity of the Oas1 proteins.
Among flaviviruses, the 3′ terminal region of the genome RNAs contains
conserved structures, despite exhibiting little sequence homology.

Many flavivirus

genomes contain regions that are rich in As and Us in their 3′ UTR immediately
following the stop codon. The sequences within these regions may be targets for RNase
L digestion which occurs at UA and UU dinucleotides. The 3′ terminal stem-loop that is
the most highly conserved of the 3′ UTR structures among divergent flaviviruses.
According to secondary structure predictions based on the whole genome fold, the next
two proximal stem-loop structures with relatively high probability of forming are located
at the end of the NS5 gene and in the 5′ region of the 3′ UTR. The RNA binding
activities of the various MBP-Oas1 fusion proteins to the three WNV 3′ probes was
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compared. Both MBP-Oas1a and MBP-Oas1a showed binding to the AU-rich probes
located at or near the 5′ end of the 3′ UTR. Neither MBP-Oas1a nor MBP-Oas1b bound
to the 3′ stem-loop at the protein concentrations tested. In contrast to the previous results
that demonstrated binding of Oas1btr to poly (I:C)-agarose (Kakuta et al., 2002), MBPOas1btr did not bind to any of the probes tested.

Results presented in this study,

demonstrate that MBP-Oas1b and MBP-Oas1a exhibit RNA binding activity to regions
of the 3′ end of the WNV genomic RNA. To our knowledge this is the first report of
specific interactions between a 2′-5′ oligoadenylate synthetase and particular regions of a
viral genome. These results suggest that if the flavivirus resistance mechanism mediated
by Oas1b involves viral RNA-protein interactions and/or protein-protein interactions,
then the truncated form of Oas1b expressed in susceptible cells would not be able to
mediate these interactions.

Future directions
The 2-5A synthetase activity of three mouse Oas1 proteins was tested in the
present study using poly (I:C). MBP-Oas1a was the only functional synthetase. In future
studies, the ability of different regions of the WNV RNA to activate Oas1 proteins will be
investigated.
Results from the present study suggest that the structures of the human and
porcine OAS1 proteins may differ from that of the mouse Oas1 proteins. Crystallization
studies and subsequent comparison of the crystal structures of the porcine OAS1 protein
and the mouse Oas1a or Oas1b proteins will require the production of large amounts of
Oas1 proteins and for this, in vitro transcription/translation systems or the
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baculovirus/insect expression system will be used. As one means of detecting cellular or
viral proteins that may interact with Oas1b, recombinant MBP-Oas1b fusion protein will
be used in in vitro pull-down and co-immunoprecipitation assays with extracts from
C3H.PRI.Flvr (resistant) or C3H/He (susceptible) cells.

Recombinant MBP-Oas1b

protein will also be used for in vivo studies of interacting partners using the Chariot
protein delivery system (Active Motif).

64
BIBLIOGRAPHY
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature.
413:732–738.
Amberg SM, Nestorowicz A, McCourt DW, Rice CM. 1994. NS2B-3 proteinasemediated processing in the yellow fever virus structural region: In vitro and in
vivo studies. J. Virol. 68:3794-3802.
Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM. 1998. Characterization of the
interferon regulatory factor-7 and its potential role in the transcription activation
of interferon A genes. J. Biol. Chem. 273:29210-17.
Baltimore D. 1968. Structure of the poliovirus replicative intermediate RNA. J. Mol.
Biol. 32:359-68.
Bandyopadhyay SK, Leonard GT, Bandyopadhyay T, Stark GR, Sen GC. 1995.
Transcriptional induction by double-stranded RNA is mediated by interferonstimulated response elements without activation of interferon-stimulated gene
factor 3. J. Biol. Chem 270:19624–29.
Bang FB. 1978. Genetic resistance of animals to viruses: Introduction and studies in
mice. Adv. Virus Res. 23:269-348.
Bauer JH, Mahaffy AF. 1930. Susceptibility of African monkeys to yellow fever. Am.
J. Hyg. 12:155-74.
Bernard KA, Maffei JG, Jones SA, Kauffman EB, Ebel GD, et al. 2001. West Nile virus
infection in birds and mosquitoes. Emerg. Infect. Dis. 7, 679-685.
Bhatt PN, Jacoby RO. 1976. Genetic resistance to lethal flavivirus encephalitis. II.
Effect of immunosuppression. J. Infect. Dis. 134:166-173.
Biron C, Sen GC. 2001. Interferons and other cytokines, pp. 321–351. In D. M. Knipe
and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott/The Williams &
Wilkins Co., Philadelphia, PA.
Blackwell JL, Brinton MA. 1995. BHK cell proteins that bind to the 3' stem-loop
structure of the West Nile virus genome RNA. J. Virol. 69:5650 58.
Blackwell JL, Brinton MA. 1997. Translation elongation factor-1α interacts with the 3'
stem-loop of West Nile virus genomic RNA. J. Virol. 71:6433 44.

65
Bowes C, Li T, Danciger M, Baxter LC Applebury ML, et al. 1990. Retinal
degeneration in the rd mouse is caused by a defect in the beta subunit of rod
cGMP-phosphodiesterase. Nature. 347:677-80.
Brinton Darnell M, Koprowski H. 1974. Genetically determined resistance to infection
with group B arboviviruses. II. Increased production of interfering particles in cell
cultures from resistant mice. J. Infect. Dis. 129: 248-56.
Brinton Darnell M, Koprowski H, Lagerspetz K. 1974. Genetically determined
resistance to infection with group B arboviruses. I. Distribution of the resistance
gene among various mouse populations and characteristics of gene expression in
vivo. J. Infect. Dis. 129:240-47.
Brinton MA. 1981. Isolation of a replication-efficient mutant of West Nile virus from a
persistently infected genetically resistant mouse cell culture. J Virol. 39:413-21.
Brinton MA. 1986. Replication of flaviviruses. In Togaviridae and Flaviviridae, The
Viruses, ed. S Schlesinger, M Schlesinger, pp. 329 76. New York: Plenum.
Brinton MA. 2002. The molecular biology of West Nile Virus: a new invader of the
western hemisphere. Annu. Rev. Microbiol. 56:371-402.
Brinton MA, Arnheiter H, Haller O. 1982. Interferon independence of genetically
controlled resistance to flaviviruses. Infect. Immun. 36: 284-88.
Brinton MA, Dispoto JH. 1988. Sequence and secondary structure analysis of the 5'
terminal region of flavivirus genome RNA. Virology. 61:3641-44.
Brinton MA,Perelygin AA. 2003. Genetic resistance to flaviviruses. Adv Virus Res.
60:43-85.
Bunning ML, Bowen RA, Cropp CB, Sullivan KG, Davis BS, et al. 2002. Experimental
infection of horses with West Nile virus. Emerg. Infect. Dis. 8:380-386.
Cahour A, Pletnev A, Vazeille-Falcoz M, Rosen L, Lai CJ. 1995. Growth-restricted
dengue virus mutants containing deletions in the 5' noncoding region of the RNA
genome. Virology 207:68 76.
Casals J, Schnider HA. 1943. Natural resistance and susceptibility to Russian springsummer encephalitis in mice. Proc. Soc. Expl. Biol. Med. 54:201-202.
Centers for Disease Control and Prevention (CDC), DVBID website. 2003.
http://www.cdc.gov/ncidod/dvbid/westnile/background.htm
Chambers TJ, Grakoui A, Rice CM. 1991. Processing of the yellow fever virus
nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B

66
are required for cleavages at dibasic sites. J. Virol. 65:6042-50.
Chambers TJ, Nestorowicz A, Amberg SM, Rice CM. 1993. Mutagenesis of the yellow
fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex
formation, and viral replication. J. Virol. 67:6797 807.
Chambers TJ, Nestorowicz A, Rice CM. 1995. Mutagenesis of the yellow fever virus
NS2B/3 cleavage site: determinants of cleavage site specificity and effects on
polyprotein processing and viral replication. J. Virol. 69:1600-5.
Chambers TJ, Weir RC, Grakoui A, McCourt DW, Bazan JF, et al. 1990. Evidence that
the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a
serine protease responsible for site-specific cleavages in the viral polyprotein.
Proc. Natl. Acad. Sci. USA 87:8898-902.
Chang YE, Laimins LA. 2000. Microarray analysis identifies interferon-inducible genes
and Stat-1 as major transcriptional targets of human papillomavirus type 31. J.
Virol. 74:4174–82.
Chu PW, Westaway EG. 1985. Replication strategy of Kunjin virus: Evidence for
recycling role of replicative form RNA as template in semiconservative and
asymmetric replication. Virology. 140:68–79.
Cleaves GR, Dubin DT. 1979. Methylation status of intracellular dengue type 2 40 S
RNA. Virology. 96:159-65.
Cleaves GR, Ryan TE, Schlesinger RW. 1981. Identification and characterization of
type 2 dengue virus replicative intermediate and replicative form RNAs.
Virology. 111:73-83.
Clemens MJ, Elia A. 1997. The double-stranded RNA-dependent protein kinase PKR:
structure and function. J. Interferon Cytokine Res. 17:503–24.
Clemens MJ, Williams BR. 1978. Inhibition of cell-free protein synthesis by
pppA2'p5'A2'p5'A: a novel oligonucleotide synthesized by interferon-treated L
cell extracts. Cell. 13:565-72.
Daly C, Reich NC. 1993. Double-stranded RNA activates novel factors that bind to the
interferon-stimulated response element. Mol. Cel.l Biol. 13:3756–64.
Daly C, Reich NC. 1995. Characterization of specific DNA-binding factors activated by
double-stranded RNA as positive regulators of interferon alpha/beta-stimulated
genes. J. Biol. Chem. 270:23739-46.
Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins. Science.
264:1415-21.

67

Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes
differentially regulated by interferon alpha, beta, or gamma using oligonucleotide
arrays. Proc. Natl. Acad. Sci. USA 95:15623–28.
Desai SY, Patel RC, Sen GC, Malhotra P, Ghadge GD, et al. 1995. Activation of
interferon-inducible 2'-5' oligoadenylate synthetase by adenoviral VAI RNA. J.
Biol. Chem. 270:3454-61.
Desai SY, Sen GC. 1997. Effects of varying lengths of double-stranded RNA on binding
and activation of 2'-5'-oligoadenylate synthetase. J. Interferon Cytokine Res.
17:531-6.
Durand B, Chevalier V, Pouillot R, Labie J, Marendat I, et al. 2002. West Nile virus
outbreak in horses, southern France, 2000: results of a serosurvey. Emerg. Infect
Dis. 8:777-782.
Eskildsen S, Justesen J, Schierup MH, Hartmann R. 2003. Characterization of the 2’-5’oligoadenylate synthetase ubiquitin-like family. Nuc. Acids Res. 31:3166-73.
Falgout B, Markoff L. 1995. Evidence that flavivirus NS1-NS2A cleavage is mediated
by membrane-bound host protease in the endoplasmic reticulum. J. Virol.
69:7232-43.
Finter NB. 1996. The naming of cats--and alpha-interferons. Lancet. 348:348-9.
Geiss GK, Carter VS, He Y, Kwieciszewski BK, Holzman T, et al. 2003. Gene
expression profiling of the cellular transcriptional network regulated by alpha/beta
interferon and its partial attenuation by the hepatitis C virus nonstructural 5A
protein. J. Virol. 77:6367–75.
Geiss GK, Gin G, Guo J, Bumgarner R, Katze MG, et al. 2001. A comprehensive view
of regulation of gene expression by double-stranded RNA-mediated cell
signaling. J. Biol. Chem. 276:30178–82.

Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang X, et al. 2002. Cellular
transcriptional profiling in influenza A virus-infected lung epithelial cells: the role
of the nonstructural NS1 protein in the evasion of the host innate defense and its
potential contribution to pandemic influenza. Proc. Natl. Acad. Sci. USA
99:10736–41.
Ghosh A, Sarkar SN, Guo W, Bandyopadhyay S, Sen GC. 1997. Enzymatic activity of
2’-5’-oligoadenylate synthetase is impaired by specific mutations that affect
oligomerization of the protein. J. Biol. Chem. 272:33220-26.

68

Ghosh A, Sarkar SN, Rowe TM, Sen GC. 2001. A specific isozyme of 2'-5'
oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2
family. J Biol. Chem. 276:25447-55.
Goodman GT, Koprowski H. 1962. Study of the mechanism of innate resistance to virus
infection. J. Cell. Comp. Physiol. 59: 333-73.
Groschel D, Koprowski H. 1965. Development of a virus-resistant inbred mouse strain
for the study of innate resistance to arbo B viruses. Arch. Gesamte. Virusforsch.
18:379-91.
Groves MG, Rosenstreich DL, Taylor BA, Osterman JV. 1980. Host defenses in
experimental scrub typhus: mapping the gene that controls natural resistance in
mice. J. Immunol. 125:1398-99.
Guo JT, Hayashi J, Seeger C. 2005. West Nile virus inhibits the signal transduction
pathway of alpha interferon. J. Virol. 79:1343-50.
Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, et al. 1990. Dengue hemorrhagic
fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med.
Hyg. 42:179-184.
Han JQ, Barton DJ. 2002. Activation and evasion of the antiviral 2'-5' oligoadenylate
synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8:512-25.
Hanson B, Koprowski H, Baron S, Buckler CE. 1969. Interferon-mediated natural
resistance of mice to arbo B virus infection. Microbios 1B:51-68.
Hartmann R, Olsen HS, Widder S, Jorgensen R, Justesen J. 1998. p59OASL, a 2'-5'
oligoadenylate synthetase like protein: a novel human gene related to the 2'-5'
oligoadenylate synthetase family. Nucleic Acids Res. 26:4121-28.

Hartmann R, Justesen J, Sarkar SN, Sen GC, Yee VC. 2003. Crystal structure of the 2'specific and double-stranded RNA-activated interferon-induced antiviral protein
2'-5' oligoadenylate synthetase. Mol. Cell. 12:1173-85.
Heinz FX, Allison SL. 2000. Structures and mechanisms in flavivirus fusion. Adv.
Virus Res. 55:231 69.
Heinz FX, Auer G, Stiasny K, Holzmann H, Mandl C, et al. 1994. The interactions of
the flavivirus envelope proteins: implications for virus entry and release. Arch.
Virol. Suppl. 9:339-48.

69
Heinz FX, Purcell MS, Gould EA, Howard CR, Houghton M, et al. 2000. Family
Flaviviridae. In Virus Taxonomy, ed. MHV Regenmortel, CM Fauquet, DHL
Bishop, EB Carstens, MK Estes, et al., pp. 860-78. San Diego: Academic Press.
Hori H, Lai CJ. 1990. Cleavage of dengue virus NS1-NS2A requires an octapeptide
sequence at the C terminus of NS1. J. Virol. 64:4573-7.
Hovanessian AG. 1991. Interferon-induced and double-stranded RNA-activated
enzymes: a specific protein kinase and 2′,5′-oligoadenylate synthetases.
Interferon Res. 11:199–205.

J.

Hovanessian AG, Wood JN. 1980. Anticellular and antiviral effects of pppA(2′p5′A)n.
Virology. 101:81-90.
Jerrells TR, Osterman JV. 1981. Host defenses in experimental scrub typhus:
inflammatory response of congenic C3H mice differing at the Ric gene. Infect.
Immun. 31:1014-22.
Jiang Z, Mak TW, Sen G, Li X. 2004. Toll-like receptor 3-mediated activation of NFkappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter
inducing IFN-beta. Proc. Natl. Acad. Sci. U S A 101:3533–38.
Johnston C, Jiang W, Chu T, Levine B. 2001. Identification of genes involved in the
host response to neurovirulent alphavirus infection. J. Virol. 75:10431-45.
Juang Y, Lowther W, Kellum M, Au WC, Lin R, et al. 1998. Primary activation of
interferon A and interferon B gene transcription by interferon regulatory factor 3.
Proc. Natl. Acad. Sci. USA 95:9837–42.
Kakuta S, Shibata S, Iwakura Y. 2002. Genomic structure of the mouse 2',5'oligoadenylate synthetase gene family. J. Interferon Cytokine Res. 22:981-993.
Khromykh AA, Westaway EG. 1996. RNA binding properties of core protein of the
flavivirus Kunjin. Arch. Virol. 141:685-99.
Knipe DM, Howley PM, eds. 2001. Fields Virology. Philadelphia: Lippincott, Williams
& Wilkins. 4th ed.
Koonin EV. 1993. Computer-assisted identification of a putative methyltransferase
domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J. Gen.
Virol. 74:733-40.
Kouri GP, Guzman MG, Bravo JR. 1987. Why dengue haemorrhagic fever in Cuba? 2.
An integral analysis. Trans. R. Soc. Trop. Med. Hyg. 81:821-3.

70
Kouri GP, Guzman MG, Bravo JR, Triana C. 1989. Dengue haemorrhagic
fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull.
World Health Organ. 67: 375-380.
Kumar A, Yang YL, Flati V, Der S, Kadereit S,et al. 1997. Deficient cytokine signaling
in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of
IRF-1 and NF-kappaB. EMBO J. 16:406–16.
Kuo MD, Chin C, Hsu SL, Shiao JY, Wang TM, et al. 1999. Characterization of the
NTPase activity of Japanese encephalitis virus NS3 protein. J. Gen. Virol.
77:2077-84.
LaVail MM, Sideman RL. 1974. C57BL/6 mice with inherited retinal degeneration.
Arch. Opthalmol. 91:394-400.
Lengyel P. 1987. Double-stranded RNA and interferon action. J. Interferon Res.7:51119.
Li H, Clum S, You S, Ebner KE, Padmanabhan R. 1999. The serine protease and RNAstimulated nucleoside triphosphatase and RNA helicase functional domains of
dengue virus type 2 NS3 converge within a region of 20 amino acids. J. Virol.
73:3108-16.
Li, W., Li, Y., Kedersha, N., Swiderick, K, Moreno, T., Anderson, P., and Brinton, M. A.
2002. Cell Proteins, TIA-1 and TIAR, Interact with the 3' Stem Loop of the West
Nile virus Complementary Minus Strand RNA. J. Virol. 76: 11989-12000.
Lin R, Heylbroeck C, Pitha PM, Hiscott J. 1998. Virus-dependent phosphorylation of
the IRF-3 transcription factor regulates nuclear translocation, transactivation
potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986–96.
Lin, R-J., Liao, C.-L., Lin, E., and Lin, Y.-L. 2004. Blocking of the alpha interferoninduced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J.
Virol. 78: 9285-94.
Lindenbach BD, Rice CM. 2001. Flaviviridae: the viruses and their replication,
p. 991-1041. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed.
Lippincott/The Williams & Wilkins Co., Philadelphia, PA.
Lindenbach BD, Rice CM. 2003. Molecular biology of flaviviruses. Adv. Virus Res.
59:23-61.
Liu WJ, Chen HB, Wang XJ, Huang H, Khromykh AA. 2004. Analysis of adaptive
mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus
nonstructural protein NS2A in inhibition of beta interferon promoter-driven
transcription. J. Virol. 78:12225-35.

71

Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, et al. 2005. Inhibition
of interferon signaling by the New York 99 strain and Kunjin subtype of West
Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural
proteins. J. Virol. 79:1934-42.
Lobigs M. 1993. Flavivirus premembrane protein cleavage and spike heterodimer
secreation requires the function of the viral proteinase NS3. Proc. Natl. Acad.
Sci. USA 90:6218-22.
Lyon MF, Kirby MC. 1993. Mouse chromosome atlas. Mouse Genome. 91:40-80.
Mackenzie JM, Jones MK, Westaway EG. 1999. Markers for trans-Golgi membranes
and the intermediate compartment localize to induced membranes with distinct
replication functions in flavivirus-infected cells. J. Virol. 73:9555-67.
Maitra RK, Silverman RH. 1998. Regulation of human immunodeficiency virus
replication by 2',5'-oligoadenylate-dependent RNase L. J. Virol. 72:1146-52.
Marie I, Durbin JE, Levy DE. 1998. Differential viral induction of distinct interferon-a
genes by positive feedback through interferon regulatory factor-7. EMBO J.
17:6660–69.
Mason PW. 1989. Maturation of Japanese encephalitis virus glycoproteins produced by
infected mammalian and mosquito cells. Virology. 169:354-64.
Mathews DH, Sabina J, Zuker M, Turner DH. 1999. Expanded Sequence Dependence
of Thermodynamic Parameters Improves Prediction of RNA Secondary Structure.
J. Mol. Biol. 288:911-40.
McAveney KM, Book ML, Ling P, Chebath J, Yu-Lee LY. 2000. Association of 2′-5′
oligoadenylate synthetase with the prolactin (PRL) receptor: Alteration in PRLinducible STA1(signal transducer and activator of transcription 1) signaling to the
IRF-1 (interferon-regulatory factor 1) promoter. Mol. Endocrinology 14:295306.
Minks MA, West DK, Benvin S, Baglioni C. 1979. Structural requirements of doublestranded RNA for the activation of 2',5'-oligo(A) polymerase and protein kinase
of interferon-treated HeLa cells. J. Biol. Chem. 254:10180-3.
Mossman KL, Macgregor PF, Rozmus JJ, Goryachev, AB, Edwards AM, et al. 2001.
Herpes simplex virus triggers and then disarms a host antiviral response. J. Virol.
75:750–58.
Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, et al.
2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of
flaviviruses. J. Virol. 79:8004-13.

72

Munoz-Jordan, J.L., Sanchez-Burgos, G.G., Laurent-Rolle, M., and Garcia-Sastre, A.
2003. Inhibition of interferon signalling by dengue virus. Proc. Natl. Acad. Sci.
USA 100:14333-38.
Murphy FA. 1980. Togavirus morphology and morphogenesis. In The Togaviruses:
Biology, Structure, Replication, ed. RW Schlesinger, pp. 241-316. Academic
Press, New York.
Nakaya T, Sato M, Hata N, Asagiri M, Suemori H,et al. 2001. Gene induction pathways
mediated by distinct IRFs during viral infection. Biochem. Biophys. Res.
Commun. 283:1150-56.
Nanduri S, Rahman F, Williams BR, Qin J. 2000. A dynamically tuned double-stranded
RNA binding mechanism for the activation of antiviral kinase PKR. EMBO J.
19:5567–74.
Perelygin AA, Lear TL, Zharkikh, Brinton MA. 2004. Structure of equine 2’-5’
oligoadenylate synthetase (Oas) gene family and FISH mapping of Oas genes to
ECA8p15-p14 and BTA17q24-25. Cytogenetic and Genome Research, In Press.
Perelygin AA, Scherbik SS, Zhulin IB, Stockman BM, Li Y, et al. 2002. Positional
cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA
99:9322-27.
Petersen LR, Roehrig JT. 2001. West Nile Virus: a reemerging global pathogen.
Emerg. Infect. Dis. 7, 611-614.
Pethel M, Falgout B, Lai CJ. 1992. Mutational analysis of the octapeptide sequence
motif at the NS1-NS2A cleavage junction of dengue type 4 virus. J. Virol.
66:7225-31.
Poidinger M, Hall RA, Mackenzie JS. 1996. Molecular characterization of the
Japanese encephalitis serocomplex of the flavivirus genus. Virology. 218, 417421.
Porterfield, JS. 1996. Encephalitis viruses: encephalitis viruses and related viruses
causing hemorrhagic disease, Academic Press, San Diego, CA.
Rice CM. 1996. Flaviviridae: the viruses and their replication. In Fields Virology, ed.
BN Fields, DM Knipe, PM Howley, pp. 931 59. Philadelphia: Lippincott-Raven.
3rd ed.
Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, et al. 1985. Nucleotide sequence
of yellow fever virus: implications for flavivirus gene expression and evolution.
Science 229:726-35

73
Reid HW, Moss R, Pow I, Buxton D. 1980. The response of three grouse species
(Tetrao urogallus, Lagopus mutus, Lagopus lagopus) to louping-ill virus.
J. Comp. Pathol. 90:257-63.
Ruiz MO, Tedesco C, McTighe TJ, Austin C, Kitron U. 2004. Environmental and social
determinants of human risk during a West Nile virus outbreak in the greater
Chicago area, 2002. Int. J. Health Geogr. 3:8.
Sabin AB. 1952. Nature of inherited resistance to viruses affecting the nervous system.
Proc. Natl. Acad. Sci. USA 38:540-46.
Samuel CE. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14: 778-809.
Sangster MY, Heliams DB, Mackenzie JS, Shellam GR. 1993. Genetic studies of
flavivirus resistance in inbred strains derived from wild mice: evidence for a new
resistance allele at the flavivirus locus (Flv). J. Virol. 67:340-47.
Sangster MY, Mackenzie JS, Shellam GR. 1998. Genetically determined resistance to
flavivirus infection in wild Mus musculus domesticus and other taxonomic groups
in the genus Mus. Arch. Virol. 143:697-715.
Sangster MY, Urosevic N, Mansfield JP, Mackenzie JS, Shellam GR. 1994. Mapping
the Flv locus controlling resistance to flaviviruses on mouse chromosome 5. J.
Virol. 68:448-52.
Sarkar SN, Bandyopadhyay S, Ghosh A, Sen GC. 1999. Enzymatic characteristics of
recombinant medium isozyme of 2'-5' oligoadenylate synthetase. J. Biol. Chem.
274:1848-55.
Sarkar SN, Miyagi M, Crabb JW, Sen GC. 2002. Identification of the substrate binding
sites of 2′-5′ Oligoadenylate synthetase. J. Biol.Chem. 277:4321-30.
Sarkar SN, Sen GC. 2004. Novel functions of proteins encoded by viral stress-inducible
genes. Pharmacology and Therapeutics. 103:245-59.
Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, et al. 1998a. Distinct and essential
roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β
gene induction. Immunity 13:539–548.
Sato M, Tanaka N, Hata N, Oda E, Taniguchi T. 1998b. Involvement of the IRF family
transcription factor IRF-3 in virus-induced activation of the IFN-β gene. FEBS
Lett. 425:112–116.
Sharp TV, Raine DA, Gewert DR, Joshi B, Jagus R, et al. 1999. Activation of the
interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein-Barr virus
RNA, EBER-1. Virology. 257:303-13.

74

Shellam GR, Sangster MY, Urosevic N. 1998. Genetic control of host resistance to
flavivirus infection in animals. Rev. Sci. Tech. 17:231-48.
Shellam GR, Urosevic N, Sangster MY, Mansfield JP, et al. 1993. Characterization of
allelic forms at the retinal degeneration (rd) and b-glucuronidase (Gus) loci for the
mapping of the flavivirus resistance (Flv) gene on mouse chromosome 5. Mouse
Genome 91: 572-74.
Shi P-Y, Li W, Brinton MA. 1996. Cell proteins bind specifically to West Nile virus
minus-strand 3' stem-loop RNA. J. Virol. 70:6278-87.
Silverman RH, Cirino NM. 1997. mRNA metabolism and post-translational gene
regulation. pp.295-309. In: D.R. Morris and J.B. Hartford, Editors, Gene
Regulation, Wiley, New York.
Smithburn KC, Haddow AJ. 1949. The susceptibility of African wild animals to yellow
fever. Am. J. Trop. Med. 29:389-423.
Smithburn KC, Hughes TP, Burke AW, Paul JH. 1940. A neurotropic virus isolated
from the blood of a native of Uganda. Am. J. Trop. Med. Hyg. 20, 471-492.
Stadler K, Allison SL, Schalich J, Heinz FX. 1997. Proteolytic activation of tickborne encephalitis virus by furin. J. Virol. 71:8475 81.
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells
respond to interferons. Annu. Rev. Biochem. 67:227–64.
Urosevic N, Silvia OJ, Sangster MY, Mansfield JP, Hodgetts SI, et al. 1999.
Development and characterization of new flavivirus-resistant mouse strains
bearing Flvr-like and Flvmr alleles from wild or wild-derived mice. J. Gen. Virol.
80:897-906.
Urosevic N, Mann K, Hodgetts SI, Shellam GR. 1997. The use of microsatellites in highresolution genetic mapping around the mouse flavivirus resistance locus (Flv).
Arbovirus Res. Aust. 7:296-99.
Vianio T. 1963. Virus and hereditary resistance in vitro behavior of West Nile (E101)
virus in cultures prepared from genetically resistant and susceptible strains of
mice. Ann. Med. Exp. Biol. Fenn. 41:1-24.
Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, et al. 1998. Virus infection
induces the assembly and coordinately activated transcription factors on the IFN-β
enhancer in vivo. Mol. Cell. 1:507-18.

75
Weaver BK, Kumar KP, Reich NC. 1998. Interferon regulatory factor 3 and CREBbinding protein/p300 are subunits of double-stranded RNA-activated transcription
factor DRAF1. Mol. Cell. Biol. 18:1359-68.
Webster LT. 1923. Microbic virulence and host susceptibility in mouse typhoid
infection. J. Exp. Med. 37:231-44.
Webster LT. 1933. Inherited and acquired factors in resistance to infection. I.
Development of resistant and susceptible lines of mice through selective breeding.
J. Exp. Med. 57:793-817.
Webster LT. 1937. Inheritance of resistance of mice to enteric bacterial and neurotropic
virus infections. J. Exp. Med. 65:261-86.
Webster LT, Johnson MS. 1941. Comparative virulence of St Louis encephalitis virus
cultured with brain tissue from innately susceptible and innately resistant mice. J.
Exp. Med. 74:489-94.
Wengler G. 1989. Cell-associated West Nile flavivirus is covered with E+ pre-M protein
heterodimers which are destroyed and reorganized by proteolytic cleavage during
virus release. J. Virol. 63:2521-26.
Wengler G, Wengler G. 1991. The carboxy-terminal part of the NS3 protein of the West
Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and
represents an RNA-stimulated NTPase. Virology 184:707-15.
Wengler G, Wengler G, Gross HJ. 1978. Studies on virus-specific nucleic acids
synthesized in vertebrate and mosquito cells infected with flaviviruses.
Virology. 89:423-37.
Wreschner DH, McCaule JW, Skehel JJ, Kerr IM. 1981. Interferon action--sequence
specificity of the ppp(A2'p)nA-dependent ribonuclease. Nature 289:414-17.
Yamshchikov VF, Compans RW. 1994. Processing of the intracellular form of the
west Nile virus capsid protein by the viral NS2B-NS3 protease: an in vitro study.
J. Virol. 68:5765-71.
Yan W, Lang M, Stein P, Pangas SA, Burns KH, et al. 2005. Mice deficient in oocytespecific oligoadenylate synthetase-like protein OAS1D display reduced fertility.
Mol. Cell. Biol. 25:4615-24.
Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida, E, et al. 1998. Direct
triggering of the type I interferon system by virus infection: activation of a
transcription factor complex containing IRF-3 and CBP/p300. EMBO J.
17:1087–95.
You S, Falgout B, Markoff L, Padmanabhan R. 2001. In vitro RNA synthesis from

76
exogenous dengue viral RNA templates requires long-range interactions between
5'- and 3'-terminal regions that influence RNA structure. J. Biol. Chem.
276:15581-91.
Zhou A, Hassel BA, Silverman RH. 1993. Expression cloning of 2-5A-dependent
RNAase: a uniquely regulated mediator of interferon action. Cell. 72:753-65.
Zhu H, Cong JP, Mamtora G, Gengiras T, Shenk T. 1998. Cellular gene expression
altered by human cytomegalovirus: global monitoring with oligonucleotide
arrays. Proc Natl Acad Sci USA 95:14470–75.
Zucher M. 2003. Mfold web server for nucleic acid folding and hybridization
prediction. Nucleic Acids Res. 31:3406-15.

